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ABSTRACT 
 
Rationale: Cardiovascular disorders are the first cause of mortality and morbidity 
worldwide. This is due, at least in part, to the poor regenerative capacity of the heart 
and the lack of drugs able to foster cardiac regeneration. Our recent work has identified 
a few human microRNAs (miRNAs), in particular hsa-miR-199a-3p, able to stimulate 
proliferation of cardiomyocytes and, once expressed in the mouse heart using viral 
vectors, to induce cardiac regeneration after myocardial infarction.  
Objective: As a first step towards clinical translation, in this study we assess the efficacy 
of the pro-regenerative miR-199a after myocardial infarction, delivered using an AAV 
vector in a pig model of ischemia-reperfusion and as a synthetic RNA molecule after a 
single intracardiac injection in mice.  
Methods and Results: We evaluated the efficacy of miR-199a in a pig model of ischemia-
reperfusion after direct myocardial injection of an AAV6 vectors carrying the miR-199a 
precursor. Cardiac function was evaluated at days 2 and 28 by gadolinium-enhanced 
cardiac magnetic resonance imaging (cMRI). The results showed significant reduction of 
infarct size and increased cardiac function in the animals treated with AAV6 miR-199a at 
one month after treatment. Histological analysis uncovered a significant increase in 
cardiomyocyte proliferation in the infarct border zone, paralleled by the expression of 
markers of cardiomyocyte de-differentiation. Despite these remarkably positive signs of 
cardiac regeneration, pigs treated with AAV6-miR-199a died of sudden death at weeks 
7-8 after treatment. In three of these pigs, clusters of small, proliferating cells with a 
phenotype of undifferentiated myogenic progenitors were apparent. 
In parallel, we comparatively analyzed the efficacy different lipid formulations in 
delivering hsa-miR-199a-3p as a naked RNA mimic in both primary neonatal rat 
cardiomyocytes and in vivo. We established a transfection protocol allowing persistence 
of miR-199a-3p mimics, carrying different chemical modifications, for at least 12 days 
after a single intracardiac injection, with minimal dispersion to other organs and long-
term preservation of miRNA functional activity, as assessed by monitoring the 
expression of two direct mRNA targets. We administered this synthetic formulation 
immediately after myocardial infarction in mice and found that a single intracardiac 
injection was sufficient to reduce scar size and improve global cardiac function up to 
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two months. Histology confirmed reduced scar extension and immunofluorescence 
showed increased cardiomyocyte proliferation in the miR-199a-3p mimic injected 
animals. 
Conclusions: AAV6-miR-199a injection after ischemia-reperfusion in pigs significantly 
improves cardiac function and reduce scar size. However, AAV6-driven miR-199a 
persistent expression in the pig myocardium is fraught with safety issues.  
A single administration of mir-199a-3p mimic is sufficient to stimulate adult mouse 
cardiac repair and restoration of cardiac function. Together, these results are 
concordant in indicating that a miRNA-based therapy aimed at inducing cardiomyocyte 
proliferation might be pursued to stimulate cardiac regeneration, however that the 
duration of the miRNA effect needs to be tightly controlled. 
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1. INTRODUCTION 
1.1 Myocardial infarction and heart failure still remain unsolved diseases 	
Heart failure is the most common outcome of cardiomyocyte dysfunction or death, 
which is most frequently caused by myocardial infarction, hypertension, valve disease, 
infection, chemotherapy or genetic cardiomyopathy [1]. 
It represents a global disease challenge that affects 38 million people worldwide [2] and 
is the leading cause of hospitalization, adverse quality of life, and death. Its survival rate 
is only 50% at 5 years, which is worse than many types of cancer, and the incidence may 
be even increasing owing to improved early survival with primary percutaneous 
coronary intervention after myocardial infarction. 
Existing therapies target the maladaptive counter-regulatory mechanisms activated in a 
chronic phase by left ventricular dysfunction after damage. After acute myocardial 
infarction, for example, loss of cardiomyocytes for ischemic death, which occurs in the 
first hours, is followed by a cascade of compensatory mechanisms, detrimental for 
global heart function. Ventricular dilatation, scar thinning and activation of interstitial 
fibrosis characterize heart remodeling weeks and months after the acute event. 
Impaired cardiac output prompts the activation of neurohormonal systems that act to 
maintain the circulation [3]. Release of angiotensin II and aldosterone drive sodium and 
fluid retention, and adrenergic system activation sustains blood pressure through 
vasoconstriction [4]. These mechanisms are primarily compensatory but become 
maladaptive, causing fluid overload, myocardial hypertrophy and slow but ongoing 
cardiomyocyte death, which leads to additional deterioration of ventricular function [3]. 
Over the last 20 years, treatments aimed to inhibit the renin-angiotensin system, 
mineralocorticoid receptor, sympathetic nervous system and natriuretic system have 
delayed just partially the progression of heart failure. Even if current drugs diminish 
mortality, they fail to address the loss of cardiomyocytes and vasculature, remaining 
intrinsically non-curative.  
Cardiomyocyte replacement to restore structural and functional integrity is the 
prerequisite of heart regeneration, which will could eventually solve the heart failure 
syndrome problem.  
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1.1.1 Evidences of heart regeneration in mammals 
 
One of the first reports documenting heart regeneration in mammals was provided by 
Porrello et al. in 2011. At post-natal day 1 (P1), mice regenerated the myocardium after 
apical resection, but this capacity was lost by 7 days of age [5]. The regenerative 
process, monitored for 2 months after injury, was characterized by cardiomyocyte 
proliferation and minimal fibrotic response. Analogously, P1 mice heart is able to 
regenerate after acute myocardial infarction induced by permanent coronary artery 
ligation by activating an extensive cardiomyocyte proliferation driven by pre-exsisting 
cardiomyocytes and, consequently, resulting in full functional recovery within 21 days 
with minimal residual scarring [6]. These reports prompt one to conclude that there is a 
possibility for endogenous heart regeneration, without the need of implanting 
exogenous cells, albeit in a limited window during the first week after birth. 
The irrefutable proof that neonatal heart regeneration occurs by pre-existing 
cardiomyocytes was given by genetic lineage tracing experiments in which 
MerCreMer+/ZEG mice had been treated with tamoxifen to irreversibly label 
cardiomyocytes with green fluorescent protein (GFP) and with [15N] thymidine to trace 
DNA synthesis in cardiomyocytes [7]. The results of this study revealed that pre-existing 
cardiomyocytes are the dominant source of cardiomyocyte replacement in mice during 
aging and after infarction. Cell cycle activation in cardiomyocytes in both conditions led 
to polyploidy and multinucleation but also to new diploid, mononucleated 
cardiomyocytes with a rate of 0.76% per year in young adult mice, which decreases 
decreased in aging animals [7]. However, in the infarct border zone of adult mice, only 
3.2% of cardiomyocytes initiate DNA synthesis and are able to unambiguously undergo 
cell division [7]. 
More recently, a few intriguing case reports supported the concept of a temporally 
privileged period of regenerative repair also in humans. A newborn infant with a large 
anterior myocardial infarction displayed healing by regeneration with full functional 
recovery 7 weeks after ischemia [8]. Another case report of functional regeneration and 
lack of scarring after cardiac corrective surgery for congenital heart disease in children 
[9] indicated that, similar to neonatal rodents, newborn humans might have the intrinsic 
capacity to repair myocardial damage and completely recover cardiac function.  
Up to now, there are no extensive studies describing cardiomyocyte proliferation after 
myocardial infarction in humans. However, histological analysis of the healthy human 
heart has identified positivity for phosphorylated histone H3 in healthy young and 
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adolescent hearts up to the age of 20 years [10], indicating that, as it occurs in mice, 
young human cardiomyocytes maintain a proliferative capacity limited to the first years 
of life. Proliferation rate in adult humans has been further studied using the worldwide 
pulse of C14 that occurred during the atmospheric testing of nuclear weapons in the 
cold war years [11]. Atmospheric C14 became incorporated into plants and entered the 
human food chain, labelling the DNA of dividing cells. After the treaty of 1963, which 
limited nuclear tests, the C14 atmospheric levels dropped rapidly. Work performed by 
C14 quantification of DNA extracted from cardiomyocytes of individuals of different age 
has indicated that cardiomyocyte renewal is age-dependent, with about 1% of cells 
being renewed per year at age 20, and 0.4% at age 75; this means that about 45% of 
cardiomyocytes are renewed over a normal lifespan, whereas 55% of cardiomyocytes 
persist since birth [11]. 
Taken together, these studies provide strong evidence for a limited regenerative 
potential of the human heart, however, the extent of endogenous proliferation is clearly 
poor to provide full cardiomyocyte replacement after myocardial infarction. 
 
1.1.2 Strategies for therapeutic regeneration 
 
Replacement of dead cardiomyocytes is the sine qua non condition to reestablish 
cardiac structural and functional integrity after myocardial infarction.  
In the last years different research lines have aimed at restoring loss of cardiomyocytes 
by: 
- Transplantation and/or activation of progenitor populations  
- Exogenous cardiomyocyte replacement (autologous or allogenic) 
- Reprogramming fibroblasts to cardiomyocytes 
- Activating pre-existing cardiomyocyte proliferation. 
 
Among the category of studies that aimed to transplant and/or activate progenitor 
populations, many efforts were made in order to replace cardiomyocyte loss with bone-
marrow derived-progenitors, which have been reported to differentiate into 
cardiomyocytes [12]. Even though the differentiation of these cells to cardiomyocytes 
was later discredited [13], many clinical trial for the treatment of acute myocardial 
infarction have been performed in the subsequent years (Strauer et al. in 2002, Perin et 
al. in 2003, BOOST in 2004, ASTAMI in 2006, REPAIR-AMI and Jannsens et al. in 2006, 
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FOCUS-CCTRN in 2012, SWISS-AMI in 2013 and REGENERATE-AMI in 2016); for meta-
analysis of these studies, cf. refs: [14] [15] [16] [17] [18] [19]	 [20] [21] [22]. The overall 
oucome of these clinical trials has indicated only modest improvement in left ventricle 
ejection fraction, which can be ascribed to the promotion of tissue survival and the 
neoangiogenetic effects of the implanted cells, exerted in a paracrine fashion. 
Several types of resident cardiac progenitor (or stem) cells have been reported to reside 
in the adult heart, recognizable by the expression of surface markers, including c-Kit, 
Sca1 or PDGFRα, or by the ability to form cardiospheres in colture [23]. The more 
studied and debated cells are the so-called c-Kit+ progenitors, which a highly disputed 
report in 2001 has shown to be able to regenerate up to 70% of the infarcted 
myocardium in mice [24]. Following that original report, a number of studies have 
followed, several of which have apparently reproduced, entirely or partially the 
originally described property of these putative c-Kit progenitors (the last relevant one 
being  by G. Ellison and N. Bernard Ginard [25], while several others disputing the effect 
(cf., among several, the study by J. Mokentin and collaborators [26]). Currently, there is 
ample consensus that these cardiac c-Kit-positive cells are not cardiogenic [27] [28]. 
The possibility to perform a large-scale production of cardiomyocytes from induced 
pluripotent stem cells [29] or embryonic stem cells (ESC) has paved the way to restore 
cardiomyocyte loss after myocardial infarction by exogenous, autologous or allogenic, 
cell transplantation. After several reports demonstrating human ESC-derived 
cardiomyocyte survival, engraftment, maturation and proliferation in rodent hearts 
after infarction [30] [29] [31] ESC- and iPS-derived cardiomyocytes were tested in non-
human primate hearts [32] [33]. The implanted cells were able to survive for at least 3 
months after transplantation and induce a very significant re-muscularization of the 
infarcted heart. The transplanted cells were perfused by host vasculature and 
synchronized to the host electrocardiogram, thus indicating electromechanical 
coupling [32] [33]. However, beside the success obtained by this study, the use of ESC- 
and iPS-derived cardiomyocytes still has significant limitations. First, 
immunosuppression is required in the case of ESC-derived cardiomyocytes, which has a 
negative impact on patient morbidity and mortality. Second, ESC- and iPS-derived 
cardiomyocytes production requires still formidable time and cost. In fact, to replace the 
loss of cardiomyocytes of a myocardial infarction in humans, at least one billion cells 
would be needed, also considering that, at the time of injection, most of the cells die or 
are washed out. Finally, but most important, ventricular arrhythmias were recorded in 
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all animals so far treated, suggesting that significant hurdles with electrical integration 
remain before human trials could safely be undertaken [34].  
 
The discovery, in 2010, that the delivery of three transcription factors GATA4, myocyte-
specific enhancer factor 2C (MEF2C) and T-box protein 5 (TBX5) is able to drive direct 
reprogramming of fibroblasts to cardiomyocytes, without an intermediate cell stage 
[35], has opened the door to the direct reprogramming in vivo. Some years later several 
other factors have been reported to be able to induce reprogramming, including as 
miR-1, miR-133, miR-208 and miR-499 [36], or to enhance reprogramming driven by the 
three factors, as HAND2 [37]. Proofs of in vivo reprogramming has been demonstrated 
in mouse models, in which transdifferentiated cardiomyocytes express sarcomeric 
proteins, are able to form gap junctions and drive sustained improvement in ventricular 
function and reduce adverse ventricular remodeling following myocardial infarction 
[37]. Considerable challenges in the direct reprogramming approach remain, including 
achieving selectivity of targeting to the heart, reprogramming human cells that have 
stable epigenetic modifications and achieving maturation of structure and function in 
reprogrammed cells. 
Among the approaches cited above, exogenous cardiomyocyte replacement (with 
autologous iPS-derived cardiomyocytes, or allogenic iPS- or ESC-derived cardiomyoctes) 
and fibroblast reprogramming might become new alterative and effective treatments 
to replace the loss of functional contractile cells. For the limitations mentioned, 
however, the possibility of their use in a clinical trial remains still quite remote.  
An alternative, currently more appealing, possibility entailsthe reactivation of 
endogenous cardiomyocyte proliferation, which will be more extensively reviewed in 
the next paragraph. 
 
1.1.3 Activation of cardiomyocyte proliferation  
	
1.1.3.1  Cell cycle regulation by targeting cyclin-CDK system 
 
The first effort to reactivate cardiomyocyte proliferation was made by targeting the 
cyclin-CDK pathway, which controls progression of the cell cycle. In particular, the 
overexpression of Cyclin A2 [38], B1 [39], and D2 [40] or the inhibition of the CDK 
inhibitors p21Waf1,  p27Kip1 and p57Kip2, effectively stimulate DNA replication in vitro. In 
addition, the overexpression of cyclin A2 and D2 also stimulates DNA synthesis in vivo. 
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Remarkably, the targeted expression of  cyclin D2 in cardiomyocytes was shown to also 
boosts repair of the injured myocardium after infarction [40].  
An alternative, interesting strategy to achieve cardiomyocytes replication is by 
modulating the levels MEIS1, a critical regulator of cardiomyocyte cell-cycle, required 
for transcriptional activation of the synergistic CDK inhibitors p15, p16 and p21 [41]. The 
deletion of this gene in mouse cardiomyocytes is sufficient to extend the postnatal 
proliferative window, and reactivate cardiomyocyte mitosis and cytokines in the adult 
heart with no apparent deleterious effects on cardiac function [41]. In contrast, the 
overexpression of MEIS1 limits neonatal heart regeneration after myocardial infarction 
[41]. 
 
1.1.3.2  Epicardial- and other growth-factor-induced cardiomyocyte proliferation 
 
A few growth factors have been shown to be able to stimulate cardiomyocytes 
proliferation. By far the most effective of these factors appears to be neuregulin1 
(NRG1), which, by binding its cognate ERBB tyrosine kinase receptors, was shown to 
induce mononuclate but not binucleated cardiomyocyte to divide [42]. It was 
suggested that soluble recombinant NRG1 injection in adult mice is sufficient to 
stimulate cell-cycle activity and promote myocardial regeneration after infarction [42], a 
finding that, however, has been later challenged [43]. Indeed, NRG1-mediated 
proliferation appears to be limited to embryonic/neonatal life up to postnatal day 7 and 
that this is promoted by its co-receptor ERBB2, the expression of which decreases after 
the first week of life [44]. Transient induction of ERBB2 after myocardial infarction 
triggers cardiomyocyte dedifferentiation and proliferation followed by re-differentiation 
and regeneration by ERK-, AKT- and GSK3/and GSK3i-mediated signaling [44].  Thus, 
NRG1 and ERBB2 are both necessary to reactivate postnatal proliferation and induce 
regeneration. An evidence of the therapeutic potential of this system came from a 
phase I trial of recombinant NRG1β3 administration in patients with chronic hear 
failure.  This study demonstrated safety of treatment and improvement of left 
ventricular function at 90 days after delivery [45]. 
  
Similar to NRG1, fibroblast growth factor 1 (FGF1) delivery, plus simultaneous inhibition 
of p38 MAP kinase, increased cardiomyocyte mitosis in 8- to 10- weeks old rats after 
myocardial infarction [46]. While p38 MAP kinase inhibition alone failed to rescue heart 
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function despite increased cardiomyocyte mitosis, FGF1 improved angiogenesis, 
possibly contributing to the survival of the newly generated cardiomyocytes [46]. 
 
More recently, it became evident that the epicardium has a role in cardiac regeneration. 
Follistatin-like 1 (FSTL1), an epicardial cardiomyogenic factor, when delivered through 
epicardial patches as a recombinant protein, boosts cell-cycle reentry and division of 
pre-exsisting cardiomyocytes, improving cardiac function and survival in mouse and 
swine models of myocardial infarction [47]. Its loss leads to maladaptive response to 
injury, while its restoration represents an effective way to reverse cardiomyocyte death 
and heart remodeling after myocardial infarction [47]. 
 
1.1.3.3  Hippo pathway modulation 
 
Hippo signaling is a conserved pathway that controls cellular proliferation and organ 
size through phosphorylation of final effectors, the transcriptional coactivators YAP and 
TAZ. In brief, in resting cardiomyocytes, YAP is maintained inactive in the cytoplasm by 
phosphorylation by a kinase cascade signaling. Mst1/2 (Hippo in Drosophila, in which 
the pathway was originally discovered by genetic screens [48] [49], in complex with 
Sav1, phosphorylates and activates LATS1/2, which associates with Mob1 and in turn 
phosphorylates and inactivates YAP. Genetic deletion of MST1, SAV1 and LATS 
determines cardiac hyperplasia [50], while overexpression of MST1 [51] or LATS2 [52] 
leads to post-natal dilated cardiomyopathy, supporting the essential role of this 
pathway in the regulation of cardiomyocyte proliferation during embryonic and fetal 
development. Consistent with this notion, transgenic mice overexpressing activated 
YAP or lacking functional Mst1 both repair myocardial injury through regeneration 
instead of fibrosis [53] [54]. 
Chromatin immunoprecipitation experiments have revealed that Hippo signaling 
negatively regulates a subset of Wnt target genes (such as Snai2 and Sox2). In Sav KO 
mice, in which YAP is constitutively activated, β-catenin is increased 4-fold in the 
nucleus of cardiomyocytes. Chromatin immunoprecipitation analysis has revealed that  
YAP interacts with β-catenin, a positive regulator of cardiac growth, and colocalize on 
common regulatory sequences downstream the Snai2 and Sox2 genes. These 
experiments suggest the existence of a mechanism by which the opposite action of 
Hippo and Wnt pathways control cardiomyocyte proliferation and heart size [50].  
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In addition, it is known that YAP activates insulin-like growth factor (IGF) signaling 
pathway in cardiomyocytes, resulting in inactivation of glycogen synthase kinase 3β 
which led to increased abundance of β-catenin [55]. Therefore, YAP couples the IGF, 
Wnt and Hippo signaling pathways with the developmental program for heart growth. 
More recent publications have disclosed a link between the Hippo pathway, the 
sarcomere and the extracellular matrix. In non-regenerative adult cardiomyocytes, 
phosphorylated YAP (the inactive form of YAP) is sequestered by destroglycan 1 (Dag1), 
a component of dystrophin-glycoprotein complex (DGC), a multiprotein 
transmembrane complex linking the actin cytoskeleton to extracellular matrix which is 
able of sensing mechanical and biomechanical inputs to inhibit YAP-mediated pro-
proliferative and pro-regenerative gene transcription [56]. In addition, the extracellular 
matrix protein agrin, during neonatal life, binds Dag1 and decreases DGC complex 
stability, subsequently leading to myofiblil disassembly and activation of downstream 
signaling molecules including YAP and ERK [57]. When agrin is overexpressed in adult 
cultured cardiomyocytes, it induces dedifferentiation and sarcomere disassembly. 
While, in vivo, a single injection of recombinant agrin promotes cardiac regeneration in 
adult mice after myocardial infarction, although the modest degree of cardiomyocyte 
proliferation suggests that there might be additional therapeutic mechanisms [57]. 	
1.2 MicroRNAs in cardiac regeneration   	
1.2.1 MicroRNA biology 
 
MicroRNAs (miRNAs) are short (20-23 nucleotides), endogenous, double-stranded RNA 
molecules that regulate gene expression by binding specific mRNAs both in 
physiological and pathological processes, including development and cancer [58]. 
The first precursor of miRNA, the pri-miRNA, is transcribed by RNA polymerase II (pri-
miRNAs are polyadenylated and capped) or by RNA polymerase III, which transcribes 
miRNAs from clusters [59]. The pri-miRNA is next cleaved by the nuclear microprocessor 
complex formed by the RNase III enzyme Drosha and the DGCR8 protein (also known as 
Pasha, Partner of Drosha) [60]. This allows the formation of pre-miRNAs, short stem loop 
structures of 65–75 nucleotides. However, the processing by Drosha/DGCR8 is not 
compulsory for every miRNA: they can derive from introns and can be released from 
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their host transcript after splicing [61]. The pre-miRNA is recognized thanks to the 
defined length of the double stranded RNA and the 3’ overhangs by Exportin-5, which 
in complex with Ran-GTP mediates the export into the cytoplasm [62]. In the cytoplasm, 
a protein complex (RISC) guides the miRNA to its target mRNAs. The assembly of RISC is 
guided by the RNase Dicer, Ago 2, the core component, and other proteins such as TRBP 
and PACT. Once in the cytoplasm, the pre-miRNA is cleaved by Dicer, which removes 
the loop and generates a 22-nucleotide miRNA duplex with two nucleotides protruding 
as overhangs at each 3’ end [63]. After this cleavage, the double strand duplex is 
separated by helicases (as p68, p72) into the functional guide strand, complementary to 
the target, and the passenger strand, which is degraded. Generally, the miRNA strand 
with the less stable base pair at its 5’ end in the duplex is loaded in RISC and will target 
the mRNA [64] [65]. The mature miRNA binds the mRNA 3’-untranslated region (3’UTR) 
and silences the target mRNA through sequestration, translational repression or mRNA 
degradation.  
MicroRNAs represent a relatively old and relevant regulatory pathway, as also testified 
by the fact that the sequences of many miRNAs are homologous among different 
organisms [64]. They act as key regulators of processes as diverse as early development, 
cell proliferation, differentiation and apoptosis, brain development, immune system 
control, angiogenesis, fat metabolism and myocardial function [66].  
MicroRNAs are fundamental for the correct cardiac development and function: Dicer 
knock-out during early stages of life or selectively in adulthood (resulting in the ablation 
of all microRNAs) causes severe heart failure and death [67]. Additionally, many gain- 
and loss-of-function studies have emphasized the role of single microRNA or microRNA 
families as regulators of cardiac disease, fostering the possibility to use these microRNAs 
as either biomarkers or targets for novel therapies [68, 69]. In particular, numerous 
microRNAs have been described as regulators of specific processes in cardiac biology as 
cardiomyocyte contractility miR-208a [70], cardiac fibrosis miR-29 [71], miR-21 [72], 
cardiomyocyte hypertrophy miR-1 [73], miR-133 [74], miR-195 [75], miR-199b [76], miR-
212/132 family [77], miR-378 [78], miR-23a [79], and cardiomyocyte proliferation miR-1 
[80], miR-133a [81], miR-199a-3p  and miR-590-3p [82].  
A detailed description of the most relevant microRNAs in the context of the induction of 
cardiomyocyte proliferation is reported in the following sections. 
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1.2.2 Anti-proliferative micro-RNAs 
 
1.2.2.1 MiR-1 
 
MiR-1 is expressed in cardiac and skeletal muscle where it is transcriptionally regulated 
by the myogenic differentiation factors, MyoD, Mef2, and serum response factor (SRF)	
[83]. MiR-1 deletion results in 3-fold upregulation of cardiomyocyte proliferation at 
postnatal day 10; however, it is also associated with large ventricular septal defects 
during embryogenesis and cardiac electrophysiology defects, by targeting IRX5, which 
determines sudden death [80]. In contrast, overexpression of miR-1 in mouse cardiac 
progenitors, where it targets the transcription factor Hand2 - which determines 
myocyte expansion - exerts a negative effect on proliferation [83].  
 
1.2.2.2 MiR-15 family 
The miR-15 family was identified from a microarray analysis as one of the strongest 
upregulated microRNAs (6-fold induction) in P10 mouse ventricles compared to P1 [6]. 
One of the members of this family, miR-195, directly targets cell cycle genes, in 
particular Chekpoint kinase I (Check-1) [84]. The precocious overexpression of miR-195 
in embrionic heart is associated with ventricular hypoplasia and ventricular septal 
defects [6]. Later on, the inhibition of the miR-15 family starting at an early postnatal 
age until adulthood increases myocyte proliferation and improves left ventricular 
systolic function after MI in adult mice [6]. This renders this miRNA an attractive 
therapeutic target to re-stimulate cardiomyocyte division for regenerative purposes. 
 
1.2.3 Pro-proliferative micro-RNAs 
 
1.2.3.1 MiR-133a  	
MiR-133a-1 and miR-133a-2, whose sequence is identical, are muscle-specific miRNAs 
regulated during muscle development [85].  Deletion of  both miR-133-1 and miR-133-2 
causes lethal ventricular-septal defects in approximately half of double-mutant 
embryos or neonates, while the other half, which survive to adulthood, succumb to 
dilated cardiomyopathy and heart failure [81]. The absence of miR-133a expression 
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leads to ectopic expression of smooth muscle genes in the heart and aberrant 
cardiomyocyte proliferation due to elevated expression of SRF and cyclin D2, which are 
targets for repression by miR-133a [81].  
 
1.2.3.2 MiR-17/92 cluster 
 
The miR-17/92 cluster was initially described as a human oncogene, richly expressed by 
a variety of human cancers [86, 87] and as a regulator of embryonic cell proliferation 
[87]. Chen et al. have demonstrated that transgenic overexpression of miR-17–92 in 
cardiomyocytes is sufficient to induce cardiomyocyte proliferation in embryonic, 
postnatal, and adult hearts [88]. In addition, overexpression of miR-17–92 in adult 
cardiomyocytes protects the heart from myocardial infarction-induced injury increasing 
cardiomyocyte proliferation by targeting phosphatase and tensin homolog (PTEN) [88]. 
 
1.2.3.3 MiR-302-367 cluster  	
The miRNA cluster miR-302-367 is expressed during early embryogenesis and is 
important for cardiomyocyte proliferation during development [89]. These microRNAs 
act by inhibiting upstream negative regulators (Mst1, Lats2, Mob1b) of the Hippo 
Pathway, which leads to the induction of embryonic cardiomyocyte proliferation by 
activating the insulin-like growth factor and Wnt signaling pathways [55]. Postnatal re-
expression of miR-302-367 reactivates cell cycling in cardiomyocytes, resulting in 
reduced scar formation after myocardial infarction [89]. However, long-term expression 
of the cluster was shown to induce cardiomyocyte dedifferentation and dysfunction, 
suggesting that persistent reactivation of the cell cycle in postnatal cardiomyocyte is 
not desirable [89]. This limitation can be overcome by transient systemic application of 
miR-302-367 mimics, leading to increased cardiomyocyte proliferation, decreased 
fibrosis, and improved function after injury without maladaptive effects. 
 
1.2.3.4 MiR-199a-3p and miR-590-3p   	
MiR-199a-3p and miR-590-3p have been identified by a high-content, fluorescence-
microscopy-based, high-throughput screening for their pro-proliferative effect in 
neonatal rodent cardiomyocytes [82]. Their capacity of boosting cardiomyocyte 
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proliferation has further been confirmed in neonatal rodent hearts after intracardiac 
injection. Finally, Eulalio et al. in our laboratory has demonstrated that microRNA 
precursors for these two miRNAs, delivered through AAV vectors, in a model of 
myocardial infarction in adult mice were able to preserve cardiac function up to two 
months after infarction by significantly increasing cardiomyocyte proliferation in the 
infarct border zone [82]. 
 
1.3 miR-199a 
There are two loci that encode the precursor of miR-199a-5p and -3p in the human 
genome; one is on chromosome 1 (miR-199a-2, miRBase Accession MI0000281) and the 
other on chromosome 19 (miR-199a-1, miRBase Accession MI0000242). The precursor of 
miR-199a used in this study to induce miR-199a-5p and -3p expression is miR-199a-1. 
MiR-199a-1 on chromosome 19 (Chr19) is embedded in the anti-sense strand of intron 
15 of the dynamin 2 (DNM2) gene, whereas miR-199a-2 on chromosome 1 (Chr1) is 
embedded in the anti-sense strand of intron 14 of the dynamin 3 (DNM3) gene [90]. 
There is no evidence of functional correlation between the expression of the dynamin 
genes and the miR-199a precursors: this may be due to the fact that the expression of 
both miRNA precursors is controlled by their own promoters (UCSC genome browser). 
Dnm3 antisense transcript contained in its intron, Dnm3os, is conserved in vertebrate 
lineages  [91] and mature microRNAs miR-199a-3p and  miR-199a-5p are conserved in 
mouse, rat, human and pig (miRBase 21). 
 
1.3.1 Regulation of miR-199a expression  
	
Currently, two main mechanisms have been described for the control of miR-199a 
expression. One is based on the regulation by transcription factors TWIST1 and EGR1 on 
Chr1 while the other one on the methylation status of miR-199a promoters on both 
Chr1 and Chr19 [90]. There is not a distinctly defined promoter region for miR-199a-1, 
therefore the region several hundreds base upstream miR-199a-1 is considered as its 
promoter region. McroRNA-199a-1 has a predicted CpG island upstream the mature 
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sequence between 130 and 540 bp [92], while miR-199a-2 has a moderately CpG-poor 
region in the promoter, which is 1349 bp long and starts 81 bp upstream the 5’ end of 
the miRNA hairpin region [93]. Several in vitro studies have shown that promoter 
regions on Chr1 and Chr19 are hypermethylated in cancer cells, while they displaye 
hypomethylated status in normal fibroblasts. Accordingly, miR-199a expression is 
higher in normal fibroblasts than in cancer cells [92].  
TWIST binds an E-box region on Dnm3os promoter and drives the expression of the 
DNM3OS transcript, which gives rise to miR-199a-2 and miR-214 [94]. Dnm3os 
regulation by TWIST depends on tissue and stage of development [95] albeit it does not 
seem to be the only factor regulating Dnm3os. 
In certain types of cancer, in fact, EGR1 was demonstrated to occupy the miR-199a-
2/miR-214 gene promoter [96]. Remarkably, a direct target of miR-199a-3p and miR-
199-5p is BRM, which is part of the catalytic subunit of the chromatin remodeling 
complex SWI/SNF. BRM is, in turn, a negative regulator of EGR1; therefore, miR-199a 
together with BRM create, as a result, a double negative feedback loop through EGR1. 
There are types of cancer expressing high levels of BRM (e.g., non-small cell lung cancer, 
breast and cervical cancer, etc.) or cancers expressing low levels of BRM (adrenocortical 
cancer, gastric cancer, cervical cancer, etc). This findings may explain the variable, low or 
high, expression of miR-199a-5p and -3 in different types of malignancies [90]. 
In addition, in the context of mice hearts, miR-199a-5p is post-transcriptionally 
downregulated by AKT [97] during hypoxia and upregulated during cardiac 
hypertrophy via β-adrenergic receptor stimulation [98]. 
 
1.3.2 MiR-199a in tumorigenesis 
 
Many efforts have been made to unravel the role and the expression pattern of miR-
199a in different cancer types. This microRNA can act as tumor suppressor, thus being 
downregulated, or it can act as an oncogene and be upregulated in specific types of 
tumors. These main differences might be due to the above described complex 
transcriptional control mechanisms, and its involvement in different cellular 
phenotypes can be ascribed to the diverse nature of its downstream targets.  
	 26	
MicroRNA-199a downregulation has been mainly studied in liver cancer, where it 
inhibits cell proliferation by targeting HIF1α [99]. It has also been found to directly 
downregulate a pro-invasion factor, DDR1, in human hepatocellular carcinoma cell line 
(HCC) [100]. Aside from liver cancer, miR-199a also showed reduced expression in other 
malignancies, such as ovarian cancer where its downregulation correlates with poor 
prognosis [101]. Other examples of miR-199a downregulation can be find in renal [102], 
breast [103] and bladder cancer [104]. 
There are cases of tumors overexpressing miR-199a, as was for the group of cancers 
characterized by down-regulation of this microRNA. For example, in pediatric 
hepatoblastoma, as opposed to adult hepatocellular carcinoma, miR-199a is up-
regulated [105]. In gastric cancer its up-regulation positively regulates cell proliferation, 
migration and invasion by targeting MAP3K11 [106].  
 
1.3.3 Antiviral effects of miR-199a 
 
In vitro studies have shown that miR-199a can inhibit HCV genome replication, 
suggesting its potential antiviral effect [107], which was further confirmed in the case of  
the hepatitis B virus [108]. Besides interacting with viral elements, miR-199a exerts its 
antiviral effects by down-regulating several transcripts along the pathways required 
and/or activated by the invading virus, including ERK/MAPK signaling, prostaglandin 
synthesis, oxidative stress signaling and PI3K/AKT signaling [109]. 	
1.3.4 MicroRNA-199a in embryonic development 
 
The antisense Dnm3os transcript contained in the Dnm3 intron, which gives rise to miR-
199a-2 and miR-214, is mostly expressed during embryonic development, while the 
Dnm3 transcript is expressed at low levels in embryonic life and at high levels in adult, 
especially in testis and brain [95]. This led to the assumption that miR-199a is 
fundamental for embryonic development. In fact, Dnm3os knock-out pups die one 
month after birth, displaying several skeletal abnormalities including craniofacial 
hypoplasia, defects in dorsal neural arches and spinous processes of the vertebrae and 
osteopenia. Thus, the Dnm3os-encoding gene appears indispensable for normal skeletal 
development and body growth in mammals [110]. 
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1.3.5 The role of miR-199a in the heart    
 
The function of miR-199a in the heart has been investigated by several studies in 
reference to its effects on proliferation, metabolism, hypertrophy, autophagy and cell 
death protection. Cardiac microRNA profiling analysis has shown that expression of 
both miR-199a and miR-214 is increased in various models of heart failure [75, 76] in 
mice and humans. The transcription of Dnm3os Dynamin3 antisense transcript is 
stimulated by pressure overload and hypoxia induced by transient aortic constriction 
(TAC) in mice [111]. Hypoxic condition in particular, leads to HIF1α activation, which, in 
turn, activates Twist1 [111]. As described above, TWIST1 recognizes an E-box region in 
the Dnm3os promoter and stimulates its transcription. Once transcribed and processed, 
both microRNAs target PPARγ, the down-regulation of which induces a shift from fatty 
acid metabolism to glycolysis, typical of failing hearts [111]. 
MicroRNA-199a-5p overexpression was further associated with hypertrophy and cell 
size regulation in both rats [112] and mice [113]. If inhibited in rat cardiomyocytes, it 
brings to cell size reduction, even after induction of hypertrophy by phenylephrine (PE), 
and increased alpha myosin heavy chain expression [112]. Moreover, its overexpression 
in vitro suppresses the anti-hypertrophic effects of Qiliqiangxin, a traditional Chinese 
medicine, which has long been used to treat chronic heart failure in patients [113].  
MicroRNA-199a was also linked to autophagy by its ability to target GSK3β, which can, 
in turn, inhibit mTOR [114]. Its overexpression leads to a reduction in autophagy and, 
consequently, to hypertrophy [114], which can be reverted in vivo by injecting 
rapamycin, an autophagy activator.   
Furthermore, miR-199a-5p can also exert negative paracrine effects on cardiac 
endothelial cells [115]. In STAT3 KO mice, which develop spontaneously heart failure, 
miR-199a-2 is up-regulated and targets ubiquitin-conjugating enzymes Ube2gi and 
Ube2i. This negative regulation causes disruption of the sarcomere structure driven by 
decreased levels of myosin heavy chain alpha and beta, troponin and tropomyosin, and 
promotes synthesis of asymmetric di-methylarginine [115], which inhibits eNOS. 
Reduced NO synthesis, in turn, causes endothelial dysfunction in mice lacking STAT3 
[115]. 
Finally, miR-199a levels greatly decrease in cardiomyocytes cultured under low oxygen 
tension [116]. This negative regulation seems to be required to stabilize p53 and to 
activate, through HIF1α, a miR-199a-5p direct target, the hypoxia pro-apoptotic genes. 
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[116]. However, if miR-199a-5p is restored, even under hypoxic conditions, this is 
sufficient to reduce apoptosis [98] [116]. 
Micro-199a-3p was also reported to exert positive effects in protecting cardiomyocytes 
from apoptosis [117]. Park and coworkers demonstrated that, in cultured primary 
cardiomyocytes, this miRNA down-regulates Ddit4, a pro-apoptotic protein, after 
ischemia/reperfusion injury. In addition, the upregulation of  miR-199a-3p and miR-214 
in cells treated with carvedilol, a β-adrenergic antagonist, promotes an anti-apoptotic 
effect through Akt activation [117]. 
 
1.4 Heart regeneration in pig models: bridge from bench to bedside    	
As stated by the Helsinki declaration (2013) [118], every new developing treatment 
aimed to reach human health must be supported by painstaking laboratory and animal 
experimentation. In vivo experiments in small animals such as rodents, provide the 
therapeutic potential for regenerative treatments. However, before applying any 
therapy to humans, large animal studies are a fundamental prerequisite to evaluate 
efficacy and safety profiles in animal models that are highly relevant to humans with 
respect to cardiac anatomy and function. Swine in particular, is the most recommended 
species for the similarities to humans in terms of cardiac and coronary anatomy and 
physiology.  Like in humans, the pig left coronary artery is usually longer and larger in 
diameter than the right coronary artery. Forty-nine percent of the left ventricle is 
supplied by the left anterior descending coronary artery (LAD), which also feeds 58% of 
the intraventricular septum [119]. Another reason for using swine models is that the size 
of these animals allows morphological and functional assessments based on clinical 
standard diagnostic tools, such as echocardiography, magnetic resonance imaging 
(MRI), computed tomography, positron emission tomography (PET) and single-photon 
emission computed tomography [120]. 
 
1.4.1 Diagnostic imaging of myocardial infarction by cardiac magnetic resonance 
 
After ischemia-reperfusion, myocardial damage and mechanical dysfunction are usually 
evaluated by echocardiography or cardiac magnetic resonance. 
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The former is frequently used in clinical settings, but displays several limitations.  It has 
notoriously imperfect acoustic windows, scant visualization of the endocardial border 
which, together with other geometric assumptions resulting from the two-dimensional 
approach affect its accuracy and reproducibility [121].  
Cardiac magnetic resonance (cMRI) is instead the golden standard technique to 
measure, with great accuracy, ejection fraction, infarct size, myocardial thickness, 
perfusion and viability and regional wall motion abnormalities. Left ventricle mass and 
volume can be measured with a standard error of 5%, making it the most reproducible 
and precise approach to measure cardiac function [122].  
 
1.4.2 Tagging cMRI – quantifing regional wall motion 	
 
Cardiac magnetic resonance allows regional myocardial deformation measurement 
without the need to implant physical markers. In 1988, Zerhouni et al. [123] established 
a new noninvasive cMRI method, known as myocardial tissue tagging, to track regional 
myocardial motion. Cardiac regions are magnetically tattooed by a grid-like geometrical 
pattern (tags), which appear as dark lines in the acquired images. Tags in two 
orthogonal direction, combined, form a grid of tissue markers which allow motion 
tracking throughout the cardiac cycle [124]. cMRI tagging allows quantitative 
measurements of intramyocardial motion such as strain. Strain analysis permits a direct 
assessment of the degree of regional myocardial deformation and its timing during the 
cardiac cycle; it is expressed as the percentage of shortening or lengthening of a small 
element of myocardium in relation to its original length [124]. Strain is calculated as: - Radial strain. The radial strain of cardiac wall is measured, along a radial 
direction, toward the center of the ventricle. Positive values mean that during 
systole myocardium is thickening, while negative values indicate dyskinesia or 
local wall thinning during systole. - Circumferential strain. Circumferential strain quantifies the intramural 
circumferential shortening. Negative values correspond to myocardial 
contraction and therefore circumferential shortening, while positive values 
indicate systolic bulging. - Longitudinal strain. Longitudinal strain quantifies myocardial shortening from 
base to apex (negative value )[124].  
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1.4.3 Late gadolinium enhancement for the quantification of myocardial infarction 
size 
 
Late gadolinium enhancement is the gold standard technique for precise quantification 
of myocardial scar tissue extension. In healthy myocardium, extracellular contrast 
agents are rapidly washed out in a time window of around 10-15 minutes, while non-
viable myocardium needs a longer time to eliminate them. After administration, 
gadolinium is rapidly removed from functional myocardium, but it is still present in the 
infarcted myocardium, thus localizes as a highlighted area by T1-weighted inversion 
recovery sequences [125]. Based on this principle, late gadolinium enhancement cMRI is 
able to detect small masses of necrotic or fibrotic myocardium. 	
1.4.4 Strategies aimed to induce cardiomyocyte proliferation in pigs 
 
As described above, mammalian cardiomyocytes lose their proliferating ability soon 
after birth [5] impeding adult heart regeneration after myocardial infarction. One 
strategy to overcome negative remodeling and heart failure is to replace cardiomyocyte 
loss by inducing pre-existing myocytes to re-enter cell cycle and replenish dead 
cardiomyocytes, thus competing with the process of scar formation. Some of the 
therapeutic strategies having this specific aim have reached experimentation in large 
animals. 
 
1.4.4.1 Gene therapy to stimulate heart regeneration in pigs 
 
A possible approach is to force the re-expression of key cell cycle regulatory genes 
which are normally silenced soon after birth in the mammalian heart [126]. One of the 
best examples was given by Shapiro et al. [127]. These authors demonstrated how 
adenovirus carrying the Ccna2 gene (encoding for cyclin A2) injection one week after 
catheter-induced myocardial infarction was sufficient to increase ejection fraction from 
35% before treatment to 42% six weeks after transgene delivery, as assessed by cMRI, 
echocardiography and LV angiography. The functional improvements reported in this 
study were correlated to a 3.5-fold increase in cardiomyocyte proliferation, as assessed 
by Ki-67 and phospho-histone3 immunofluorescence. Accordingly, fibrosis was higher 
in non treated animal infarct zones, while Ccna2-treated animal displayed a higher 
number of healthy cardiomyocytes and a reduced infarct size which was not 
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accompanied by an increased cardiomyocyte hypertrophy [127]. In any experimental 
approach, such the one presented by Shapiro et al., entailing the use of cell cycle 
regulators, precautions must be in place to prevent unwanted effects in extracardiac 
tissues, due to the potential for oncogenic transformation. These safety concerns would 
necessitate tissue-specific activation of cyclin A2, or the adoption of molecular 
strategies for its transient expression. 
Quite surprisingly, gene therapy with two main angiogenic factors was also reported to 
increase cardiomyocyte proliferation in pigs [128]. In a study by Tao et al., the delivery of 
VEGF and Ang1 cDNAs through adeno-associated viral vectors (AAVs) immediately after 
LAD ligation was sufficient to improve cardiac function and myocardial perfusion 
assessed by single-photon emission computed tomography 2 and 8 weeks after 
infarction. Treated animals displayed a massive induction of angiogenesis, reduction of 
cell apoptosis and increased cardiomyocte proliferation through activation of Akt 
kinase and up-regulation of cyclin D2/cdk4 and cyclin A/cdk2 [128]. However, the 
contribution of the pro-proliferative effect was quite modest, and heart function 
amelioration was massively attributed to protection from cell death [128].  
 
1.4.4.2 Recombinant protein delivery to stimulate heart regeneration in pigs  
 
Aiming at boosting cardiomyocyte proliferation, Wei et al. identified an epicardial 
factor, follistatin-like-1 (Fslt1) [47], the expression of which is lost after damage in 
mammals, as a potent cardiogenic protein in mouse and pig models. Patches of 
recombinant Flst1 protein applied to pig epicardium one week after MI induction, 
stimulated recovery of cardiac function - ejection fraction, as measured by cMRI, 
increased from 30% to 40% two weeks post patch implantation  by increasing 
cardiomyocyte proliferation and stimulating arteriogenesis [47].  
Finally, the results of a study in which IGF-1 and HGF were delivered alone or in 
combination with a self-healing hydrogel one month after infarction, also appear worth 
mentioning. In this case, echocardiography measurements demonstrated significant 
improvement in ejection fraction and LV end-systolic volumes 4 weeks after delivery 
[129]. Functional parameter improvements and reduction in scar size were correlated 
with an almost 4-fold increase in cardiomyocyte proliferation and a 2-fold increase in 
the number of the endogenous c-Kit positive, CD45 negative cardiac stem/progenitor 
cells in the infarcted area [129]. 
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1.4.4.3 microRNA-based strategies to restore cardiac function in pigs  
 
Up to date, there are no reports about any microRNA exerting a pro-proliferative effect 
on cardiomyocytes  in a swine model of acute myocardial infarction .  
However, approaches modulating microRNAs have already been tested in an MI model 
in pigs to protect myocardium from ischemia-reperfusion injury or to promote 
angiogenesis. 
Strategies aimed at the inhibition of miR-92 were used to protect from 
ischemia/reperfusion injury [130] and to induce new vessel formation [131]. An LNA 
antisense directed against miR-92a, applied regionally after MI induction by balloon 
occlusion, was able to reduce scar size one week after infarction from 55% to 35% 
(control versus treated animals) [130] and to significantly increase ejection fraction, 
evaluated by hemodynamic measurements. The mechanism by which the inhibition of 
miR-92 protects from ischemia/reperfusion injury is explained by halved cardiomyocyte 
death, increase in the number of capillaries and by significant reduction of 
ischemia/reperfusion-induced inflammation [130]. The delivery of miR-92a was 
additionally achieved exploiting poly-lactide-co-glycolide (PLGA) microspheres, which 
prolonged miRNA inhibition for at least 10 days [131]. The persistent miR-92a inhibition 
reduced regional-wall motion dysfunction one month after injury [131]. 
 
1.5. Adeno-associated viral vectors (AAVs) 
 
Adeno-Associated  Viral Vectors are non-enveloped, single stranded (ss) DNA viruses 
with a diameter of 18-25 nm which belong to the family of Parvoviridae and the genus 
Dependovirus. These viruses are not able to replicate autonomously; in fact, wild-type 
AAV infection depends on the super-infection with another virus [132]. The first factor 
identified as a successful helper in the generation of AAV particles was Adenovirus, 
hence the name [132]. Around one hundred of different wild-type AAV serotypes have 
been identified to date, each one displaying a specific tropism for different tissues, not 
necessarily related to the  ability to bind specific cell surface primary receptors, since 
most serotypes make use of ubiquitous, cell surface proteins for docking to the cell 
surface and internalization through endocytosis. However, despite the high sero-
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prevalence of AAV in the human population, the virus has never been linked to any 
human pathology. 
 
1.5.1 Genome organization 
 
AAV has a linear DNA genome of about 4.7 kb and contains two open reading frames, 
corresponding to the genes rep and cap, flanked by 145 nt-long inverted terminal 
repeats (ITRs), in which the first 125 nucleotides constitute a palindrome, which folds 
upon itself forming a T-shaped hairpin structure, identical at the two viral ends 
[133].The ITRs, due to their structure, provide a free 3’ hydroxyl group that is essential 
for the initiation of viral DNA replication by a cellular DNA polymerase in a primase-
independent manner [134]. Due to their importance in AAV biology, the ITRs are the 
only sequences maintained during the generation of recombinant AAV vectors. 
The rep region codes for replication-related proteins, while the cap region codes for the 
three structural proteins, VP1, VP2, and VP3, which together form the viral capsid [135] 
Rep and Cap transcripts are produced from their respective promoters p5, p19 and p40. 
The four Rep protein isoforms, namely Rep78, 68, 52 and 40, have helicase and ATPase 
activity but only Rep78 and Rep68 have strand- and site-specific endonuclease and site-
specific DNA binding activities. Rep78 and Rep68 in particular, bind specific sites within 
the ITRs, and are required for viral DNA replication and site-specific integration. On the 
contrary, Rep52 and Rep40 are involved in the generation of single-stranded viral 
genomes for packaging into AAV capsids [135]. The structural proteins VP1, VP2 and 
VP3 (transcribed from the cap gene from the p40 promoter) assemble together in the 
ratio of 1:1:18, generating a capsid shell with icosahedral symmetry and a diameter of 
18-25 nm [136]. Each viral particle contains the viral genome in the form of a single 
stranded DNA molecule having either positive or negative polarity [136]. In addition, 
the VP1 protein also contains a phospholipase A2 (PLA2) motif, fundamental for AAV 
escape from the endosomes [137]. 	
1.5.2 AAV infection 	
1.5.2.1 Docking onto the cell membrane 
 
The first step in AAV infection consists in the binding of the virus to specific receptors, 
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which mediates its entry inside the cell. Heparan sulfate proteoglycan (HSPG) is the 
primary receptor for AAV2, AAV3 [138]; sialic acid for AAV1, AAV4, AAV5, AAV6; the 
37/67 kDa laminin receptor for AAV8; and N-linked glycans with terminal galactosyl 
residues for AAV9. Additionally, the virus takes advantage of the binding to cellular co-
receptors such as the growth factor receptors FGF, PDGF and HGF or the integrins aVb5 
and a5b1, important for the efficiency of infection and for determining cellular 
selectivity of the different serotypes. Finally, a recent study has described a 
transmembrane protein, AAVR, as a general key receptor for AAV, fundamental for 
binding and internalization [139].  	
1.5.2.2 Endocytosis 
  
After receptor binding, internalization is the next step in the AAV viral entry pathway 
trough clathrin-coated vesicles. For a successful AAV infection to occur, the viral 
particles need to escape from these endocytic vesicles which is mainly mediated by the 
activity of the viral phospholipase A2 [137] motif (HDXXY), which is present at the N-
terminal of VP1 [137]. The lowering of pH inside these compartments during their 
maturation from early to late endosomes, determine a conformational change in VP1, 
which mediates the exposure of the N-terminal ends of the protein, containing the 
vPLA2 domain as well as nuclear localization signals (NLS) [137] [140]. The VP1 PLA2 
domain induces pore formation in the endocytic vesicles, thus allowing the virus to 
escape while the exposed NLS mediates translocation of the virion into the nucleus 
[140] [141]. 	
1.5.2.3 Nuclear entry 
 
The mechanisms underlying nuclear translocation of the virus across the nuclear 
membrane are still incompletely understood. A recent report  has shown that nuclear 
entry of rAAV2 is mainly dependent on the canonical nuclear import pathway, involving 
an active importin-β mechanism [140].  The timing and dynamics of virion uncoating  
are also still debated. Sessiseberger et al. reported the presence of GFP-labeled AAV 
viral capsids into the nucleus, thus suggesting that viral uncoating occurs after nuclear 
entry [142] whilst, Lux et al. originally showed that viral uncoating occurs before and 
during nuclear entry [143]. A more recent study, however, has demonstrated that AAV2 
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virions enter the nucleus and accumulate in the nucleolus, thus confirming that viral 
uncoating occurs inside the nucleus [144].  	
1.5.2.4 Genome processing and new viral particles synthesis 
 
After virion uncoating, the free AAV ssDNA genomes must be converted into dsDNA to 
be transcribed. In a few hours, every cell produces 5x105-1x106 viral particles; the 
infected cells eventually are lysed and the virions released outside them. The molecular 
determinants governing cell permissivity to productive AAV replication are still largely 
unclear. A number of treatments increase the efficiency this process, including DNA-
damaging agents (ultraviolet, gamma-irradiation, X-radiation, alkylating agents, 
radiomimetic drugs, etc.), agents that inhibit DNA synthesis (hydroxyurea), thereby 
suggesting that DNA damage repair (DDR) mechanisms may be involved in 
transduction [145]. Indeed, the AAV genome, similar to damaged cellular DNA, is single-
stranded and bears imperfectly paired DNA sequences at the level of its terminal 
hairpins [146] [147]. These proteins block replication of the genome by impeding its 
conversion to a double-stranded form. Once a cell is treated with chemical or physical 
agents, its DDR proteins are diverted to other sites of DNA damage, thus permitting the 
AAV genome to complete its replication. 
 
1.5.3 Recombinant AAV  
 
The characteristics of AAV life cycle, including its defectiveness and ability to persist in 
infected cells as a latent viral genome, early suggested that this virus could be an 
excellent tool for in vivo gene transfer [148]. Between the ITRs, an expression cassette is 
cloned containing the therapeutic gene and its regulatory elements. Any kind of 
promoter is suitable for the expression of the insert, whose size is restricted to a 
maximum of 4 - 4.5 kb. The ITR sequences of the parental virus are the only required cis 
elements for viral genome replication and its packaging into viral particles. The rep gene 
is removed from the vector DNA genome, therefore allowing the persistence of AAV 
inside non-dividing cells mainly as extrachromosomal, concatameric DNA. To date, 
rAAV preparations are mostly based on a helper-free method, which entails the 
transfection of HEK293 cells with three plasmids: 1) an AAV2-ITR-containing plasmid 
carrying the gene of interest; 2) a plasmid carrying the Rep-Cap of the desired serotype; 
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a plasmid expressing the helper genes (E4, VA, E2A) from Adenovirus.  
Recombinant AAV vectors of different serotypes have been shown to be very efficient in 
transducing post-mitotic tissues such as brain (AAV9), heart (AAV9 [149], rAAV6 [150]), 
retina (photoreceptors; rAAV5, rAAV8 [151]), skeletal muscle (myofibers; rAAV1, rAAV6 
and rAAV7 [152] [153]), liver (rAAV8 and rAAV9 [154]) and pancreas (endocrine/exocrine 
pancreas; rAAV8, rAAV6 [155]). 
1.6. Chemical modifications of miRNA-based therapeutics  	
In just two decades, since their discovery, the field of miRNA biology has expanded 
considerably. Accumulating insights into their roles in development and disease have 
turned miRNAs into attractive tools and targets for novel therapeutic approaches.  
There are two ways to approach a miRNA-based therapeutic intervention: i) using 
strategies to upregulate a specific miRNA through miRNA mimics or ii) exploiting 
inhibitors of miRNAs (antimiRs) to obtain the reduction in the levels of an endogenous 
miRNA. 
MiRNA mimics are synthetic, double-stranded small RNA molecules the sequence of 
which corresponds to the endogenous miRNA and consequently exerts its function. On 
the contrary, antimiRs are single stranded oligonucleotides designed to block and 
inhibit a target miRNA [156]. 
The main challenge for RNA-based therapeutic strategies (for both single- or double- 
stranded oligonucleotides) is the risk of oligonucleotide degradation by RNases in 
serum or in the endocytic compartment of cells, together with the possible recognition 
by the immune system [157]. Therefore, in the past years, many efforts have been made 
in in achieving increased oligonucleotide half-life in vivo, playing with different 
chemical modifications or, on the other hand, in developing delivery vehicles to 
encapsulate RNA for protection and allow endosomal escape.  
While over the past years most of the studies have focused on miRNA inhibition, a few 
successful methods have also been devised to deliver miRNA mimics. As a matter of 
fact, miRNA mimicry approaches mainly use the same chemical modification of antimiRs 
to increase oligonucleotide half-life. To therapeutically transfect a miRNA mimic, it is 
convenient to deliver synthetic RNA duplexes that harbour chemical modifications to 
improve stability and cellular uptake [158]. In miRNA mimics, the strand identical to the 
miRNA of interest is the guide (“antisense” as referred to the target mRNAs, strand), 
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whereas the opposite (“sense” or “passenger”) is less stable and can be associated to a 
molecule, such as cholesterol, to enhance cellular uptake. Furthermore, the passenger 
strand might contain chemical modifications to prevent its loading into the RISC or it 
can even be unmodified to ensure rapid degradation [159]. One example was given by 
the work of Montgomery and colleagues, who described the development of a 
functional miR-29 mimic to target pulmonary fibrosis [160]. The sense, passenger strand 
(identical to the target mRNAs) contained a 2’-OMe modification to prevent loading into 
RISC, while the antisense, active strand (complementary to the target miRNA) contained 
a uracil-uracil overhang at the 3’ end to increase stability, and was phosphorylated at 5’ 
end [160].  
The modification that antisense strand can undergo are limited because of the need, for 
the RNA molecule, to be recognized by RISC. The 2’-fluoro (2’-F) modification renders 
the guide strand more stable because of its function in protecting against exonucleases, 
without interfering with RISC loading [161]. The most commonly used sugar 
modifications are 2’-O-methyl ribose-modified RNA (2’-OMe), 2’-O-methoxyethyl (2’-
MOE) RNA and locked nucleic acid (LNA) which improve the resistance to nuclease and 
increase the melting temperature, leading to a thermodynamically strong duplex 
formation with complementary RNA [162]. Among the cited sugar modifications, LNAs 
exhibits the highest affinity toward complementary RNA with an increased Tmelting  of +2-
8°C per introduced LNA modification [163], while 2’-MOE modifications have superior 
binding affinity, efficacy and nuclease resistance compared to 2’-OMe [164].  
In addition, increased nuclease resistance can be achieved by substituting the 
phosphodiester backbone linkages with phosphorothioate linkages [165]. Apart from 
nuclease resistance, phosphorothioate modifications also enhance binding to plasma 
proteins, leading to reduced clearance by glomerular filtration and urinary secretion. 
Therefore, phosphorothioate-modified oligonucleotides display noticeably improved 
pharmacokinetic properties, facilitating their delivery into many peripheral tissues in 
vivo [166].
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2. MATERIAL AND METHODS  	
All the laboratory reagents, used in this study are listed in Table1 and were purchased 
from standard suppliers. All the solutions were prepared with MilliQ (Millipore) water 
and, if required, solutions were sterile filtered (0.22 μm pores) before use.  
 
2.1. Cell biology protocols  
 
2.1.1 Isolation and culture of primary neonatal rat/mouse ventricular cardiomyocytes 	
Wistar rats and CD1 mice were purchased from Charles River Laboratories Italia Srl. 
Animal care and treatments were conducted in conformity with institutional guidelines 
in compliance with national and international laws and policies (EEC Council Directive 
86/609, OJL 358, December 12, 1987).  
After neonatal rats/mice sacrifice by cervical dislocation and organ harvesting, 
ventricles were separated from the atria, cut into smaller pieces and digested at room 
temperature using 1.75mg/ml trypsin (BDmDifco) and 10 μg/ml DNaseI (SIGMA) in 
CBFHH buffer (calcium and bicarbonate-free Hanks with HEPES). The collected 
supernatant was centrifuged to separate the cells, which were subsequently re-
suspended in DMEM, high glucose supplemented with vitamin B12 (Sigma), 5% of fetal 
bovine serum (FBS, Life Technologies) and with 100U/ml of penicillin and 100 μg/ml of 
streptomycin (Pen-Strep, Sigma). The collected cells were passed through a cell strainer 
(40 μm, BD Falcon) and seeded on uncoated 100 mm dishes (DB Falcon) for 2 hours at 
37°C in 5% CO2. After this passage, cardiomyocytes were mainly present in the 
supernatant. Cardiomyocytes were counted and plated at the desired density in DMEM, 
high glucose supplemented with vitamin B12 (Sigma), 5% of fetal bovine serum (FBS, 
Life Technologies) and with 100 U/ml of penicillin and 100 μg/ml of streptomycin (Pen-
Strep, Sigma) in primary or collagen coated plates. 
 
2.1.2 Isolation and culture of human fetal ventricular CMs cardiomyocytes 	
Upon Burlo Garofalo Children Hospital Ethical Commettee approval, 17-22 week 
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gestation human abortive foetus hearts were excised at Burlo Garofalo Hospital, Trieste, 
and immediately transported in Krebs-Ringer solution (10 mM Hepes; 129 mM NaCl; 4.7 
mM KCl; 1.2 mM KH2PO4; 1.2 mM MgSO4 x 2H2O; 5 mM NaHCO3; 5,5 mM glucose; 2 
mg/ml BSA; 20 mM taurine; 2 mM carnitine; 5 mM creatine; 30 mM butanedione 
monoxime buffered at pH 7.4) at 4°C to the International Center for Genetic Engineering 
and Biotechbology (ICGEB), Trieste. The myocardium was cut into small pieces after 
careful removal of pericardial traces. The digestion solution was prepared immediately 
before the experiment with 1.75 mg/ml trypsin (BDmDifco) and 10 μg/ml DNaseI 
(SIGMA) in CBFHH buffer (calcium and bicarbonate-free Hanks with HEPES) and added 
to heart fragments, which underwent a total of 8 digestions step at 37°C. The 
supernatants of each step were collected and centrifuged to separate the cells, which 
were subsequently re-suspended in DMEM high glucose supplemented with vitamin 
B12 (Sigma), 5% fetal bovine serum (FBS, Life Technologies) and 100 U/ml of penicillin 
plus 100 μg/ml of streptomycin (Pen-Strep, Sigma). The collected cells were passed 
through a cell strainer (40 μm, BD Falcon) to eliminate undigested fragments of tissue. 
Human fetal cardiomyocytes did not require any pre-plating, therefore we immediatly 
plated them, after counting, at the desired density in DMEM high glucose 
supplemented with vitamin B12 (Sigma), 5% of fetal bovine serum (FBS, Life 
Technologies) and with 100 U/ml of penicillin and 100 μg/ml of streptomycin (Pen-
Strep, Sigma) on primary or collagen coated plates. 
 
2.1.3 Transfection of neonatal rat and human fetal CMs with microRNA mimics 	
The microRNA mimics were transfected into neonatal rat and human fetal CMs using a 
standard transfection protocol, at a final microRNA concentration of 25 nM. The 
following procedure and volumes refer to a well of a 96 multiwell plate.  
The transfection reagent (Lipofectamine RNAiMAX, LifeTechnologies) was diluted in 
OPTI-MEM (Life Technologies) and incubated for 5 minutes. The transfection mixture 
was added to 1.5 ml Eppendorf Tubes containing each microRNA mimic (500 nM 
concentrated) and incubated for 30 minutes. The mixture was than transferred into 
each well, where 1.0*104 cells had been seeded 24 hours before (final volume 150 μ
l/well) in DMEM high glucose supplemented with vitamin B12 (Sigma), 5% of fetal 
bovine serum (FBS, Life Technologies) and without antibiotics. 
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MicroRNA mimic transfection protocol for 96 well plates format, volumes per well: 
− 7.5 μl of microRNA mimic at the concentration of 500nM 
− 24.8 μl of OPTI-MEM 
− 0.2 μl of RNAiMAX 
Protocol: 
1. Incubate RNAiMAX and Opti-MEM medium (Gibco) for 5 minutes at RT 
2. Dispense 25 μl/well of transfection mix into 1.5ml eppendorf tube containing 7.5 μl 
/well of microRNA (500nM);  
3. Incubate for 30 minutes at RT 
4. Dispense 32.5 μl of mix/well on top of previously seeded rat CMs 1.0 *10^4 cells/well 
(150 μl final volume) in medium described above, without antibiotics 
5. 24 hours after transfection change the medium with fresh DMEM, high glucose 
supplemented with vitamin B12 (Sigma), 5% of fetal bovine serum (FBS, Life 
Technologies) and with 100 U/ml of penicillin and 100 μg/ml of streptomycin (Pen-
Strep, Sigma) 
6. Incubate for 72 hours 
7. Wash the cells 2 times in PBS (100 μl/well) 
8. Fix the cells in 4% PFA (50 μl/well) 
 
2.1.4 Transfection of mouse cardiomyocytes with microRNA mimics 	
MicroRNA mimic transfection of mouse CMs requires the same protocol for rat CMs 
described above. However, the final concentration of microRNA mimics was optimized 
at 50 nM for mouse CMs instead of 25 nM for rat CMs. 
 
2.1.5 Cardiomyocyte transduction  	
The day after plating, cell colture medium was replaced with fresh complete one 
(DMEM, high glucose supplemented with vitamin B12, 5% of fetal bovine serum and 
with 100 U/ml of penicillin and 100 μg/ml of streptomycin) and cells has been 
transduced with AAV6 considering 1*104 viral particles per cell, following this formula: 
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 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 ∗  (1x10! 𝑣𝑖𝑟𝑎𝑙 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙) (𝑣𝑖𝑟𝑎𝑙 𝑡𝑖𝑡𝑒𝑟)  
 
2.2. Molecular biology protocols  	
2.2.1.Total DNA isolation from organs  	
After sacrifice, the different organs were removed by gross dissection from treated pigs, 
washed in PBS and snap frozen in liquid nitrogen. DNA was isolated using DNeasy Blood 
& Tissue Kit following manufacturer’s instruction. This kit provides a fast and easy silica-
based DNA purification method on convenient to use spin-columns. Samples can be 
directly lysed with proteinase K, eliminating the need for mechanical disruption and 
reducing hands-on time.  
 
2.2.2.Total RNA isolation from organs and cultured CMs 	
Total RNA was extracted from organ or organ fragments prepared and stored at -80°C as 
described in the previous paragraph. For RNA extraction, 1 ml of TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) was added to each samples (maximum weight 50 mg) 
and the tissue was efficiently disrupted using the MagNA Lyser Beads in the dedicated 
Instrument (Roche).  
Total RNA was also exttracted from cultured rat or mouse CMs. In this case, cells were 
washed in PBS and directly lysed using TRIzol reagent (1ml for ≅250 thousands CMs) 
(Invitrogen, Carlsbad, CA, USA).  
After either tissue homogenization or cell lysis, TRIzol was recovered and RNA extracted 
using the miRneasy mini kit (Qiagen), according to the manufacturer’s instructions. 
 
2.2.3 Quantification of nucleic acids by real-time PCR 	
Total DNA was used as a template for realtime PCR to detect the presence of the 
sequence of the AAV vector in fragments of heart tissue as well as of other different 
organs. To this end, we used primers together with a TaqMan® probe (Applied 
Biosystems, Foster City, CA, USA) to specifically detect the CMV promoter contained in 
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our vectors. The exact number of molecules of the vector per microgram of total DNA 
was quantified by the simultaneous amplification of a standard curve of known quantity 
of a plasmid containing the target sequence. In parallel, vector genomes were also 
quantified using the housekeeping 18S rRNA gene as a normalizer (Thermofisher 
Scientific). 
Total RNA extracted from our sample tissues was quantified at Nanodrop and reverse-
transcribed using hexameric random primers (Invitrogen), starting from 1 μg of RNA. 
The cDNA was used as a template for realtime PCR amplification to detect the 
expression levels of selected genes. The housekeeping gene GAPDH was used to 
normalize the results. Quantification of gene expression was performed by quantitative 
real-time PCR, using the TaqMan® assays (Applied Biosystems) reported in Table 2.  
The protocol reported here below has been tested to ensure a reaction efficiency of 2: 
• Each reaction was composed in 20 μl: 
i) 10 μl 2X PCR Master Mix (Biorad); 
ii) 1 μl 20X primers and probe fluorofore FAM 
iii) 1 μl cDNA 
iv) H2O to final volume. 
• The quantitative RT-PCR entailed these passages: 
i) 95°C 5 minutes 
ii) 44 cycles: 
1. 95°C 10 seconds 
2. 60°C 30 seconds 
3. Read. 
Then the relative quantitation has been normalized to the reference gene using the 2–
ΔΔCT (Livak) method. 
 
2.2.4 Quantification of miRNA by Mircury LNA universal RT microRNA PCR  	
MiR-199a-3p and 5p were quantified by real time PCR using miRCURY LNA Universal RT 
microRNA PCR system (Exilent Syber Green Master Mix, Exiqon) with cDNA previously 
retro-transcribed by Universal cDNA Synthesis kit (Exiqon) according to the 
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manufacturer’s protocol. The primers used were hsa-miR-199a-3p LNA PCR primer set 
UniRT and hsa-miR-199a-5p LNA PCR primer set UniRT (Exiqon), which recognize both 
endogenous pig/mouse/rat/human microRNA and AAV-driven microRNA expression 
since the sequence in 100% conserved in pig, human, mouse and rat. The housekeeping 
gene used for normalization was 5S (Exiqon). MicroRNAs were quantified according to 
the following procedure: 
• Each reaction was composed in 10 μl: 
i) 5 μl PCR Master mix (Exiqon) 
ii) 1 μl PCR primer set (Exiqon) 
iii) 4 μl diluted cDNA template  
• The quantitative RT-PCR entailed these passages: 
i) 95˚C 10 min 
ii) 45 cycles: 
1) 95˚C 10 s 
2) 60˚C 1 min 
3) ramp-rate 1.6˚C/s 
4) Optical read 
• Melting curve analysis 
Then the relative quantitation has been normalized to the reference gene: The 2–ΔΔ
CT (Livak) Method has been used. 
 
2.2.5 Immunofluorescence on culture rat and mouse cardiomyocytes (96 multiwell) and ATP 
level measurement 	
Cells were fixed with 40 μl of 4% paraformaldehyde (PFA) for 15 min, permeabilized 
with 40 μl of 0.5% Triton X-100 in phosphate buffered saline (PBS) solution for 10 min, 
followed by 1 hour blocking in 40 μl of 1% bovine serum albumin (BSA, Roche). Cells 
were then stained overnight at 4°C in blocking solution (BSA 1% in PBS) plus mouse 
monoclonal antibody against sarcomeric α-actinin 1:400 (Abcam). Cells were washed 
with 100 μl PBS and incubated for 2 hours, at room temperature, with the selected 
secondary antibody labelled with Alexa Fluor-488 (green) or Alexa Fluor-594 (red). Cell 
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nuclei were further stained with 100μl of Hoechst 33342 (Life Technologies) diluted 
1:5000 in PBS. Alternatively, for cell viability assay, cells were processed 72 hours after 
transfection using the ATPlite™ Luminescence Assay (PerkinElmer) according to the 
manufacturer’s protocol. Luminescence was measured by a Wallac EnVisionTM 2104 
MultiLabel Reader (PerkinElmer). 
 
2.2.6 EdU Staining in 96 multiwell  	
When indicated, cells were further processed using the Click-IT EdU 594 Imaging kit to 
reveal EdU incorporation, according to the manufacturer’s instructions. Cell nuclei were 
further stained with 100μl of Hoechst 33342 (Life Technologies) diluted 1:5000 in PBS. 
 
2.2.7 Production and purification of recombinant AAV vectors  	
Recombinant AAV vectors used in this research project were prepared by the AAV 
Vector Unit of the International Centre for Genetic Engineering and Biotechnology, in 
Trieste (http://www.icgeb.org/avu-core-facility.html), as described previously [82] with a 
few modifications. Shortly, recombinant replication defective AAV particles were 
generated in HEK293T cell cultures in roller bottles by a cross-packaging approach 
whereby the vector genome was packaged into capsid serotype-6. Consequently, viral 
stocks were purified by PEG precipitation from clarified cell lysates and cell culture 
supernatant followed by two consecutive CsCl2 gradient centrifugations. Full viral 
particles obtained by the gradient were extensively dialyzed in PBS and stored in 
aliquots at -80°C until use.  
Recombinant AAVs titer was determined by quantifying vector genomes (vg) packaged 
into viral particles by real-time PCR against a standard curve of a plasmid containing the 
vector genome. Viral titers obtained for this study were around 1x1013 vg per milliliter. 
 
2.3. Histology 	
At the end of the studies, animals were weighted and sacrificed by injection of 10% KCl, 
to stop the heart at diastole. Heart, lungs, liver, spleen and kidneys were explanted and 
weighted immediately after sacrifice. The whole organs were rinsed in PBS and fixed in 
10% formalin at room temperature. Fixed heart was sectioned as described in Results 
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sections, Figure 6 F. Organ chuncks were embedded in paraffin and further processed 
for histology. 
 
2.3.1 Masson’s trichrome stain 	
Masson’s trichrome characteristically stains keratin and muscle fibers in red, collagen 
and bone in blue, cytoplasm in pink, and cell nuclei in dark brown to black. This colour 
pattern is achieved by the combination of four different stains: Weigert’s iron 
hematoxylin for nuclei, picric acid for erythrocytes, a mixture of acid dyes (acid fuchsin, 
”ponceau de xylidine”) for cytoplasm and aniline blue for connective tissue. Tissue 
paraffin sections were deparaffinised (65°C for 12 hours and xylene or bioclear for 2 
hours at room temperature), rehydrated (5’-100% EtOh; 5’-95% EtOh, 5’-75% EtOh, 5’-
50% EtOh, H2O) and processed using a commercially available kit for Masson’s trichrome 
stain (BioOptica), according to the manufacturer’s instructions. Later, slides were 
dehydrated (5’-50% EtOh; 5’-75% EtOh, 5’-95% EtOh, 5’-100% EtOh, H20) and mounted 
in Eukitt mounting medium by Sigma. Fibrosis content was measured on 4x 
magnification images using ImageJ. Briefly, ImageJ treshold was used to measure blue 
area (represents fibrosis) which was expressed as percentage of the whole section area. 
 
2.3.2 Periodic acid-Shiff (PAS) stain 	
The Periodic acid-Shiff (PAS) stain detects glycogen, glycoproteins, glycolipids and 
mucins in tissues. Periodic acid stain works by oxidising glycols to aldehydes. Aldehydes 
then react with the Schiff reagent and releases a pararosaniline adduct, which stains the 
glycol-containing cellular elements in purple. Paraffin slides were deparaffinised (65°C 
for 12 hours and xylene or bioclear for 2 hours at room temperature), rehydrated (5 min 
-100% EtOh; 5 min - 95% EtOh, 5’-75% EtOh,5’-50% EtOh, H2O) and processed using the 
PAS staining kit (SigmaAldrich) to detect fibre border, according to the manufacturer’s 
instructions. Slides were then dehydrated (5’-50% EtOh; 5’-75% EtOh, 5’-95% EtOh, 5’-
100% EtOh, H2O) and mounted in Eukitt mounting medium by Sigma. 
 
2.3.3. Immunohiystochemistry 	
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Tissue paraffin sections were deparaffinised at 65°C for 12 hours and immersed in 
xylene or bioclear for 2 hours at room temperature and rehydrated (5 min -100% EtOh; 5 
min -95% EtOh, 5 min -75% EtOh, 5 min -50% EtOh, H2O). Antigen retrival was 
performed by boiling sections in sodium citratre 0.1 M pH 6.0, 0.05% Tween 20 for 20 
minutes and letting them cool down at room temperature for 2 hours. They were 
subsequently rinsed twice in water and twice in TBS (5 minutes each at room 
temperature). Permeabilization was performed by soaking slides in TBS-triton 0.1% for 
10 minutes, followed by two washes TBS-triton 0.025% of 1 minute each. Sections were 
further blocked in 10% horse serum, 1% BSA in TBS one hour at room temperature and 
incubated with primary antibodies 1:100 or 1:150, depending on the antibody, at 4°C 
overnight in TBS-BSA 1%, anti-GATA4 (Abcam), anti-desmin (Roche), anti-Myogenin 
(Cell Marque), anti-Endothelin receptor 1 (Abcam), anti-WT1 (Cell Marque), anti-CD34 
(Roche), anti-CD45 (Roche) and anti-Ki-67 (Roche). The following day, after three washes 
in TBS-triton 0.025% at room temperature, tissue endogenous peroxidase was 
inactivated by incubation for 20 minutes at room temperature with 3% H2O2. Hydrogen 
peroxidase was washed three times with TBS-triton 0.025% and sections incubated with 
appropriate biotin-conjugate secondary antibody (Abcam) 1:400 in TBS-BSA 1% for 1 
hour at room temperature. Following three washings with 0.025% TBS-triton, the signal 
was amplified incubating the section with Avidin–Biotin-Complex-HRP (ABC KIT Elite- 
PK-6100, Standard, VECTASTAIN) solution for 30 minutes. After three washes with 
0.025% TBS-triton, the immunohistochemical-complex was visualized by exposure to (3, 
3 -diaminobenzidine) DAB solutions (ImmPACT DAB, SK-4105, VECTOR) for 3 to 
10 minutes. The sections were rinsed with distilled water (dH2O), stained with 10 drops 
of hematoxylin for 2 minutes and then washed in water for 2 minutes. Following one 
quick wash in alchol/acid solution, sections were washed 30 seconds in water, and then 
soaked 2 minutes in Scott-blue-solution that provided rapid and precise blueing of 
nuclear chromatin and nuclear membranes. After 30 seconds of washing in water, the 
sections were quickly dehydrated in ascending concentrations of alcohol (5 min -50% 
EtOh; 5 min -75% EtOh, 5 min -95% EtOh, 5 min -100% EtOh,) and xylene, before being 
cover-slipped with Eukitt mounting medium. 
 
2.3.4 Analysis of BrdU incorporation and immunofluorescence  	
To assess cardiomyocyte proliferation, infarcted pigs received BrdU (Sigma; 10 mg/kg) 
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intramuscular injections, every day for 10 days. After euthanasia, pig hearts were 
excised, cut in pieces as described in Results section (Figure 6 F) and briefly washed in 
PBS, fixed in 10% formalin at room temperature and embedded in paraffin. Samples 
were cut into 4μm tissue sections, de-waxed in xylene for 2 hours and rehydrated with 
alcohols at decreasing concentration (100, 90, 70, 50%) at room temperature. Antigen 
retrival was performed by boiling sections in sodium citratre 0.1 M pH 6.0, 0.05% Tween 
20 for 20 minutes and letting them cool down at room temperature for 2 hours. 
Sections were rinsed three times in water and permeabilized 30 minutes in 1% Triton 
X100 in PBS. DNA denaturation was performed by incubating 10 minutes in 1M HCl on 
ice and 20 minutes in 2M HCl at 37°C. Cells were incubated with 0.1 M sodium-borate 
buffer pH 8.4 for 12 minutes at room temperature, then washed three times with PBS 
and then blocked for 1 h in 10% horse serum PBS. Tissue sections were stained 
overnight at 4°C in 1:100 anti-α-actinin antibody (Abcam) in 5% horse serum PBS and 
in 1:100 anti-BrdU (Abcam), washed 3 times 10 min in PBS at room temperature and 
incubated 1 hour in 1:200 appropriate secondary antibody conjugated to Alexa Fluor-
488 and Alexa Fluor-594 (Life Technologies). Sections were further washed three times 
in PBS and stained with Hoechst 33342 (Life Technologies). Antibodies for histone H3 
phosphorylation at serine 10 and and ki-67 were from Millipore and Abcam respectively; 
assays were performed as described above. To measure cardiomyocyte cross sectional 
area, lectin Wheat Germ Agglutinin (WGA; Vector Labs) 1:100 was added together with 
the secondary antibody and incubated as described above.  
 
2.3.5 TUNEL assay 	
For analysis of TUNEL in vivo, heart fragments were fixed overnight in PFA 4%. 
Cryosections were obtained after 24h incubation in sucrose 20%, rinsed in PBS, 
permeabilized 15 min in 0.5% Triton X100 PBS, and then blocked for 1 h in 1% BSA in 
PBS. Tissue sections were stained overnight at 4°C in 1:100 anti-α-actinin monoclonal 
mouse antibody (Abcam) in 1% BSA in PBS, washed 3 times in PBS at room temperature 
and incubated 1 h in 1:500 secondary antibody conjugated to Alexa Fluor-488 (Life 
Technologies). TUNEL assay (Roche) was performed, according to the manufacturer’s 
instructions. Nuclei were further stained with Hoechst 33342 (Life Technologies). 
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2.4. Surgical instrumentation in pigs  	
Pig experiments described in the following section were performed at the Istituto di 
Fisiologia Clinica of the Italian CNR, Pisa, Italy by Doctor Kathia Gabisonia, under the 
supervision of Professor Fabio Recchia. 
Animal care and treatment were conducted in conformity with institutional guidelines 
in compliance with national and international laws and policies (European and 
Economic Council Directive 86/609, OJL 358, December 12,1987) after having obtained 
specific consensus from the Italian Ministry of Health. 
 
2.4.1 Pig Experimental Protocol  	
Three- to four-month-old healthy farm pigs underwent ischemia-reperfusion and AAV 
injection as described in the following section. Cardiac magnetic resonance imaging 
(cMRI) was performed at 2 days and 1, 4 and 8 weeks after myocardial infarction.  
Ten additional infarcted pigs, 5 receiving AAV6-miR-199a and 5 AAV6-Control, were 
injected intramuscularly every day for 10 days, starting from two days after surgery, with 
the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU, Sigma; 10 mg/kg) re-
suspended in 50% PBS and 50% DMSO. At day 12 after infarction, animals were 
sacrificed and organs were harvested as described above. Additionally, ten infarcted 
pigs (5 receiving AAV6-miR-199a and 5 AAV6-Control) were injected intramuscularly 
every day for 10 days with BrdU from day 20 after surgery, to the day of sacrifice, day 30. 
After completion of the protocol, animals were sacrificed by arresting hearts in diastole 
with a i.v. injection of 10 ml of a saturated KCl solution (in bolus) and the chest was 
opened. Heart was sectioned as described in the Results section, Figure 6 F. 
 
2.4.2 Myocardial infarction in pigs  	
Three to four month old male farm pigs, of 32-35 kg body weight, were fasted for 12 
hours before surgery and received antibiotics and analgesics. Animals were sedated 
with an intramuscular injection of zoletil 8 mg/kg and ear vein and artery were 
cannulated for drug infusion and pressure monitoring, respectively. General anesthesia 
was subsequently induced with propofol (2–4 mg/kg). Immediately after, pigs were 
intubated by using an endotracheal tube and ventilated. Inhalatory anaesthesia was 
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kept by 2% isoflurane. Electrocardiogram, heart rate and arterial pressure were 
continuously monitored during the whole procedure. Thirty minutes before coronary 
occlusion, pigs received of amiodarone to prevent arrhythmias. Thoracotomy was 
performed by cutting the left forth intercostal space, and the pericardial sac was 
opened to expose the heart. The LAD was isolated from surrounding tissue distal to the 
first diagonal branch and closed by a suture. The two ends of the suture were threaded 
through a plastic tube and were cross-clamped after tightening to achieve coronary 
artery occlusion. LAD occlusion occurence was confirmed by the presence of ST 
elevation in the electrocardiogram and ventricular arrhythmias. In the case of 
ventricular fibrillation (VF), direct cardiac massage was performed with a frequency of 
100/min and continued during the period of arrhythmia until the pigs were able to 
maintain the systolic pressure in normal ranges. Open-chest epicardial defibrillations 
were frequently necessary, and amiodarone and adrenaline were administered between 
the electrical discharge at 3-5 min intervals. After 90 minutes, coronary occlusion was 
removed to start the reperfusion phase. Subsequently, after 10 minutes of reperfusion, 
the animals were randomized in 2 groups receiving 2x1013 AAV6-Control (AAV6 carring 
an empty polylinker) or 2x1013 AAV6-miR-199a. Viral particles were suspended in a final 
volume of 2 ml in PBS and delivered as 20 direct injections in myocardium (100 μl per 
injection site), equally distributed along the border zone, identified as the margin of 
ischemic myocardium, pale compared to normally perfused myocardium. Three of the 
injection sites were marked with epicardial stitches which served as reference points for 
tissue sampling and histological analyses 12 days, 4 or 8 weeks after the open chest 
surgery. After injections, the chest was closed in layers, and the pneumothorax was 
reduced. In addition, a group of sham operated animals served as normal controls. The 
artificial ventilation was gradually suspended and antibiotics and analgesics were given 
after surgery. 
 
2.4.3. Testing different AAV serotypes in pigs  	
In order to identify the AAV serotype able to transduce most efficiently pig hearts, 3 pigs 
were operated as described in the former section and 1x1012 viral particles of AAV6, 
AAV8, 9 carrying  the EGFP gene were injected intramyocardially into the anterior wall 
of the left ventricle, in different sites marked with epicedial stitches. One month after 
injection, animals were euthanized, cardiac tissue was harvested from the injection sites 
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and each sample was snap frozen for DNA vector and transgene RNA expression 
quantification. 
 
2.4.4 CMRI measurements in pigs 	
Swine were sedated with tiletamine hydrochloride and zolazepam hydrochloride and 
anesthesia was maintained by continuous infusion of propofol on spontaneous 
respiration. Animals were layed in a right lateral position with the heart at the isocenter 
on MRI unit. ECG leads were placed on the chest for vectorial gating image acquisition. 
Cine-MRI images were acquired with a 1.5 T scanner (Signa Excite HD; GE Medical 
Systems, Waukesha, WI, USA), using a non-breath-hold ECG gated, multi-NEX steady-
state free precession pulse. LV functional parameters and infarct scar size were assessed 
following as described previously [167]. The heart was scanned along two long axis 
views (vertical and horizontal) and with a set of short axis views from atrioventricular 
valve plane to the apex as shown in Figure 6 G. Tagging-CMR images were acquired 
with an electrocardiography-gated, segmented K-space, fast gradient recalled echo 
pulse sequence with spatial modulation of magnetization to generate a grid tag 
pattern.  
To assess the presence of the scar and quantify the extension of post infarction fibrosis, 
delayed enhanced images were acquired in two-dimensional T1 weighted segmented 
inversion recovery-prepared gradient echo-sequence 10 min after administration Gd-
DTPA (0.2 mmol/kg iv) in short- and long-axis views correspondent to those of Cine-
CMR.  
 
2.5 CMRI data analyses  	
2.5.1 LV global and regional function  	
Global LV functional parameters, end-diastolic volume and end-systolic volume, 
ejection fraction, cardiac output, and left ventricular regional wall thickening (LVWT) 
were measured as previously described [167]. 
The end-diastolic and end-systolic volumes, together with other measurements (cardiac 
mass, EF, CO, LVWT) were automatically calculated by the commercially available 
research software package (Mass Analysis, Leyden, The Netherlands) upon manual trace 
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of LV endocardial and epicardial borders on all short-axis cine images at the end-
diastolic and end-systolic frames.  
Regional contractility was assessed by three indexes: 
- end-systolic radial wall thickening (WT%). 
- LV circumferential strain in short-axis slices (basal, middle, and apical). 
- LV radial strain in short-axis slices (basal, middle, and apical).  
The area of interest for the three measurements was the middle slice, which is 
orthogonal to LV long axis at 30% of its length starting from the apex. It was divided 
into 8 equal circumferential segments and the connection of the right ventricle to the 
left ventricle was defined as reference point for the segmentation. The 8 regions of the 
myocardium were: anterior (A), anterolateral (AL), lateral (L), inferolateral (IL), inferior (I), 
inferoseptal (IS), septal (S), anteroseptal (AS), and the region were acute ischemia and 
AAV injection was performed is the anterior as Figure 9 A and B shows. 
LV contours drawn in the short-axis frames (Mass Analysis, Leiden, The Netherlands) 
were needed to calculate end-systolic and end-diastolic wall thicknesses. The 
percentage of WT (wall thickening) is calculated as follows:  
WT = (EST-EDT) /EDT x 100 
where EST was end-systolic thickness and EDT was end-diastolic thickness. EST, EDT and 
WT walues for each of the 8 segments were plotted to generate the curve and the area 
under curve (AUC) which was further used for statistical analyses.  
Strain was calculated as the percent change of length in a specific direction where L0 is 
the original fiber length before deformation and L is current length (Lagrangian 
formula):  
Strain (EL)=(L- L0)/ L0 (%)  
Tagged cardiac images were analyzed using a custom software based on the method by 
Bogaert et al.	[168].  
All the data were blinded analyzed under the supervision of of a III-level EACVI 
(European association of cardiovascular imaging) cardiac MRI accreditated cardiologist. 
 
2.5.2 Myocardial fibrosis  	
To determine the size of the fibrosis after infarction, gadolinium delayed contrast-
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enhanced (Gd-DE) images in short axis view were acquired 10 min after intravenous 
administration of the contrast agent. The T1-weighted, short axis images were obtained 
in mid systole to decrease artefacts of premature ventricular complexes. The infarct 
zone was defined as area with SI > 5 SD above the mean SI of remote region.  
All the data were blinded analyzed under the supervision of of a III-level EACVI 
(European association of cardiovascular imaging) cardiac MRI accreditated cardiologist. 
 
2.5.3 Infarct core and peri-infarct area  	
The images acquired by Gd-DE were analyzed using custom-designed software to 
differentiate the dense infarct core from the heterogeneous peri- infarct area, or gray 
zone. The infarct core and peri-infarct area were quantified as a percentage of total 
myocardium endocardial upon manual trace of epicardial borders on the delayed-
enhancement short-axis slices. The infarct core was defined as area with SI (signal 
density) >5 SD (standard deviation) above the mean SI of contralateral remote region of 
the myocardium, while gray zone was considered to have SI between 3 and 5 SD above 
normal myocardium.  
Finally, the infarction core and the gray zone were quantified as a percentage of the 
total myocardium and as a percentage of the total infarct size [169]. 
All the data were blinded analyzed under the supervision of of a III-level EACVI 
(European association of cardiovascular imaging) cardiac MRI accreditated cardiologist. 
 
2.5.4 Myocardial edema, area at risk and myocardial salvage  	
Infarct-related edema was considered present when the signal intensity on T2-weighted 
images was 2 times more of the mean SI of normal myocardium. Edema was manually 
traced on T2-weighted, short-axis images. Tissue weight in grams was calculated as the 
the product of myocardial volume and density (1.05 g/cm3). Percentage of area at risk 
and myocardial salvage index were calculated as follow:  
AAR (%) = Myocardial Edema (%) (at day 2) - Final Scar Size (%) (at 4 weeks)  
Myocardial Salvage Index (%) = (AAR % / Myocardial Edema % ) X 100 
All the data were blinded analyzed under the supervision of of a III-level EACVI 
(European association of cardiovascular imaging) cardiac MRI accreditated cardiologist. 
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2.6 Surgical instrumentation in mice 	
The following section describes experiment made in the Bioexperimental facility at 
ICGEB, Trieste. 
Animal care and treatment were conducted in conformity with institutional guidelines 
in compliance with national and international lawsand policies (European and 
Economic Council Directive 86/609, OJL 358, December 12,1987). 
 
2.6.1 Intra-cardiac miRNA injection and MI 	
Intracardiac microRNA mimic injection and myocardial infarction induction have been 
extensively described in Lesizza et al. [170]. Briefly, CD1 mice were anesthetized by 
intraperithoneal injection of ketamine-xylazine (40 mg/kg-100 mg/kg, Imalgene 1000 
and Sigma respectively), at a dosage of 1.2-1.3 μl/g and and intubated. Torax was 
incised, the 5th intercostal space was cut and enlarged to expose heart anterior wall. 
Twenty microliters of a mix of miRNA and lipids (ratio 1:1 in volume) was injected into 
the left ventricle. After injection torax was sutured mice were extubated to re-establish 
normal breathing. Lipid-mediated intracardiac miRNA delivery efficiency, animals 
received 200 pMoles of microRNA mimics (all from Dharmacon) mixed with 10 μl lipids, 
according to the manufacturers’ specific protocols, in a total volume of 20 μl. In order 
to evaluate efficacy of miRNA transfection after MI, in a set of animals (n=13-20 per 
group) the anterior wall left anterior descending coronary artery was ligated 1 mm 
below the left atrium auricula. After myocardial infarction induction, intracardiac 
injection was performed after ligation as described above. 
 
2.6.2 Echocardiography analysis 	
Heart function function was evaluated by echocardiography analysis as extensively 
described in Lesizza et al. [170]. Echocardiography was performed in anaesthetized 
mice 1, 2, 4 and 8 weeks after MI, using a Vevo 2100 Ultrasound (Visual Sonics) equipped 
with a MS550D 22–50 MHz linear array solid-state transducer. 
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2.7 Statistical analysis 	
Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was 
performed by using a commercially available software package (GraphPad Prism). 
Differences among groups were compared by one- and two-way ANOVA followed by 
the Bonferroni post-hoc test. In particular, one-way ANOVA with Bonferroni post-hoc 
test has been used to compare means of two or more samples in order to determine 
whether there is statistical evidence that the associated population means are 
significantly different (e.g. Figure 5 E), while two-way ANOVA has been used to compare 
the effect of different treatments with multiple observations at different timepoint (e.g. 
Figure 25 A-C). 
For survival analysis, Kaplan-Meier survival curve was generated and log-rank statistics 
test was rendered. For regional wall motion data, the area under the curve (AUC) was 
acquired by trapezoidal rule and analyses performed by one- and two-way ANOVA.  
For all the statistical analyses, significance was accepted at P<0.05. 
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3. RESULTS 	
PART 1 – EFFICACY OF PRO-PROLIFERATIVE miRNAs IN HUMAN CARDIOMYOCYTES 
 
The overall goal of this PhD project was to provide proof-of-principle evidence that a 
miRNA mimic therapy aimed at stimulating cardiomyocyte proliferation might be 
effective at inducing cardiac regeneration in a large animal model after MI, thus paving 
the way to possible clinical translation in humans. This work followed a previous study 
that identified, through a high throughput screening approach entailing the analysis of 
over 950 human miRNAs, those mimics that were active in stimulating proliferation of 
both mouse and rat primary neonatal cardiomyocytes [82].  
 
3.1 Identification of the most effective microRNAs at inducing human cardiomyocyte 
proliferation 	
A first, fundamental step was to identify, among the miRNAs that were effective in 
rodent cells, those that were also active in human cardiomyocytes. In particular, for this 
analysis we concentrated our attention on 8 human microRNAs (hsa-miR-18a, hsa-miR-
30e, hsa-miR-33b, hsa-miR-199a, hsa-miR-302d, hsa-miR-590, hsa-miR-1248 and hsa-
miR-1825). Two of these miRNAs (miR-199a-3p and miR-30e-3p) are conserved among 
mouse, rat, human and pig, while others are not fully conserved or have been identified 
only in humans so far, according to miRbase release 21 (http://www.mirbase.org; Figure 
4).  
To obtain primary human cardiomyocytes, we set up a protocol to mechanically and 
enzymatically isolate human cardiomyocytes from 17-22-week-old-gestation abortive 
foetuses, which were obtained from the Children Hospital in Trieste upon ethical 
approval and consent. In brief, the developed protocol entailed heart explant and 
transportation to the laboratory, followed by isolation of ventricles, digestion of 
myocardial tissue with trypsin while pipetting for mechanical disaggregation of the 
tissue, followed by recovery of supernatants containing cardiomyocytes and plating 
(Figure 5 A). 
As shown in Figure 5 B human fetal cardiomyocytes, displayed a rod shape structure 
during isolation, while they became flat after 4 days of culture. First we wanted to assess 
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permissivity of these cells to transduction using different AAV serotypes. AAV vector 
preparations expressing EGFP and corresponding to AAV6, AAV8 and AAV9 were used 
to transduce primary human fetal cardiomyocytes (1x104 v.g. per cell; data not shown). 
AAV6 was found to be the most effective (Figure 5 B) and was therefore used for all the 
subsequent experiments.  
We tested the 8 selected microRNAs either as transgenes encoded by AAV6 or as 
transfected synthetic miRNA mimics (Figure 5 D-G) in isolated cardiomyocytes, 
identified by a marker of skeletal and cardiac muscle, sarcomeric-α -actinin. 
Cardiomyocyte proliferation was assessed by evaluating the percentage of cells that 
incorporated the nucleotide analogue EdU over 48 hours (Figure 5 D-G). Analysis of 
cells transfected with miRNA mimics using a lipofectamine-based carrier indicated that 
miR-33b*, miR-302d, miR-199a-3p and miR-1825 were able to significantly increase 
cardiomyocyte proliferation compared to untreated cells, or control cells treated with 
carrier alone or C. elegans miR-67 (P<0.01 for miR-33b*, miR-302d, with an increased of 
over 10-fold; P<0.05 for miR-199a-3p and miR-1825; Figure 5 D and E). In contrast, the 
extent of proliferation was markedly lower (maximum 1.5 fold over controls) in cells 
transduced with the corresponding AAV6 vectors. In this case, the effective miRNAs 
were miR-30e, miR-33b, miR-1248, miR-1825 (P<0.01) and miR-199a-3p (P<0.05; Figure 
5 F and G). Of notice, miR-590, the most effective miRNA in driving mouse 
cardiomyocyte proliferation in our original screening [82] was ineffective as a mimic and 
even detrimental when its pre-miRNA DNA was delivered using the AAV6 vector. This 
result can be rationalized considering that, when expressed from AAV, both the 5p and 
3p are produced, at ratio that might be different in each cell type and with ultimate 
cumulative effects that are unpredictable and possibly variable in different species. 
 
PART 2 – EFFECT OF AAV-miR-199A DELIVERY AFTER MYOCARDIAL INFARCTION IN 
PIGS 
 
3.2.1 AAV6 efficiently transduces porcine myocardium 	
AAV vectors of serotypes 6, 8 and 9 have been reported to transduce efficiently post-
mitotic muscle fibres and cardiomyocytes, however with efficiency that varies among 
species, delivery route and in vivo vs. ex vivo application (reviewed in ref. [171]. We thus 
compared efficiency of AAV6, AAV8 and AAV9 carrying the reporter gene EGFP to select 
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the serotype with the highest transduction efficiency in the porcine myocardium. 
Vectors were injected into the left ventricular (LV) wall of 3 pigs (1x1012 v.g. per injection 
per animal) and, one month later, viral DNA and EGFP mRNA were quantified in tissue 
samples. AAV6 displayed the highest transduction efficiency (Figure 6 A and B) and 
was thus selected for the rest of this study.  
 
3.2.2 Persistent expression of miR-199a after AAV6-mediated delivery in infarcted 
pigs  	
Myocardial infarction (MI) was induced in 19 male farm pigs (3-4 months old) by 
occluding the left anterior descending coronary artery below the second diagonal 
branch during open-chest surgery. The occlusion was released 90 minutes later and, at 
10 minutes of reperfusion, the animals were randomly divided into 2 groups receiving 
2x1013 empty AAV6 (AAV6-Control, n=9) or 2x1013 AAV6-hsa-miR-199a (AAV6-miR-199a, 
n=10). An additional group of sham operated animals served as normal controls (n=6). 
AAVs were administered by a blinded operator who performed 20 injections directly in 
myocardium through the epicardium (100 µl of viral suspension per injection site). 
Injections were equally distributed along the infarct border zone of LV, which was 
identified by the operator as the margin of pale, ischemic myocardium (Figure 6 C-E).  
Some of the injection sites were tagged with epicardial stitches, hence myocardial 
samples in the corresponding territories could be easily detected and sampled post-
mortem for histological analysis (as shown in Figure 6 F).  
Animals from both groups that were sacrificed at 28 (AAV6-Control, n=4; AAV6-miR-
199a, n=5) and additional infarcted animals sacrificed at 12 days, with or without 
infarction (n=3) were analysed for levels of transduction and transgene expression. The 
levels of hsa-miR-199a-3p in the injected areas were increased >18 and >27 folds at 12 
and 28 days, respectively, compared to endogenous levels (P<0.01 in both cases; Figure 
6 G and H), consistent with persistence of functional AAV transduction in the 
myocardium [171]. The levels of viral DNA in the myocardium of the injected animals 
were >18 times than those in the liver and >40 times than in other organs (liver, spleen, 
kidney and lung; Figure 6 L). The levels of hsa-miR-199a-3p RNA were not significantly 
increased in any other analysed organ, except the heart (Figure 6 M). No overt signs of 
pathology, including hyper-proliferation (as assessed by Ki-67 staining) were observed 
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(data not shown). Thus, AAV6 transduction and transgene expression remain relatively 
localized at the sites of intracardiac injection. 
 
3.2.3 AAV6-miR-199a reduces post-infarct scar size  	
Cardiac morpho-functional assessment was performed using cardiac magnetic 
resonance imaging (CMRI). Nineteen infarcted pigs were scanned at 4 weeks post-MI, 
while half of them, randomly selected from both the AAV6-miR-199a and AAV6-Control 
groups (n=5 and n=4 respectively), were also scanned at 2 days post-MI to quantify 
ischemic myocardial edema, measures as enhanced T2-weighted signals in CMRI 
(Figure 7 A). No significant differences were detected between the two groups 
(30±4.7% vs 35±32.5% in AAV6-miR-199a and AAV6-Control groups respectively; Figure 
7 B). Although myocardial infarct-related edema is not universally accepted as fully 
equivalent to the area at risk (i.e. the entire myocardial perfusion bed distal to the 
occluded coronary artery), still it was a surrogate marker to indicate similar extension of 
the infarct areas in the two groups. 
The mass of damaged myocardium was identified and quantified by CMRI based on 
gadolinium delayed contrast-enhanced images (late gadolinium enhancement, LGE). At 
2 days post-MI, the gadolinium-retaining region, defined as either infarct mass or size, 
was not significantly different between the two groups, indicating similar extent of 
initial myocardial damage (Figure 7 C), also in agreement with the measurements of 
edema. At 4 weeks post-MI, scar mass and size in the AAV-Control group were both 
unchanged compared to gadolinium retaining-myocardium quantified at day 2; in 
contrast, in the AAV6-miR-199a group there was over 50% reduction in both 
measurements (LGE mass 7±2 vs 15±2.5 at 28 days, % LGE size 13±3.2% vs 23±4% at 28 
days; P<0.01; Figure 7 C).  
Representative LGE-CMRI images showing 5 cross-sectional planes (a-e, Figure 7 G) of 
hearts from 2 pigs in the AAV-Control and 2 pigs in the AAV-miR-199a groups at days 2 
and 28 after MI are shown in Figure 7 F. A marked reduction in scar size at day 28 
compared to the damaged area at day 2 is appreciable in the animals which received 
AAV-miR-199a-a. For two representative animals, gross anatomy of cardiac slices with 
corresponding LGE-MRI images in AAV6-Control and AAV6-miR-199a at day 28 after MI 
are shown in Figure 7 D and E respectively.  
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The infarct region included a "core" fibrotic area and a surrounding "gray zone", 
comprising a mixture of viable myocardium and fibrotic areas (Figure 7 H). At 28 days 
post-MI, the core was significantly smaller in the AAV6-miR-199a group, while the gray 
zone was not significantly different between the two groups, consistent with a lower 
core/gray zone ratio in the group that benefited from miR-199a expression (infarct core 
mass 5±1 vs 12±2.5; core/gray zone ratio 5±1 vs 3±0.7; P<0.01; Figure 7 I). The reduced 
scar size and the increased proportion of mixed tissue compared to fully fibrous tissue 
were suggestive of a process of regeneration in previously damaged regions after 
delivery of miR-199a.  
 
3.2.4 Recovery of global and regional cardiac function in miR-199a-treated animals 
at one month after MI 	
Multiple functional parameters were analysed by CMRI in animals treated with AAV6-
Control and AAV6-miR-199a which displayed not significantly different heart rates. LV 
ejection fraction was significantly depressed at day 2 after MI in both groups, however 
selectively recovered at 28 days in animals injected with AAV6-miR-199a while it further 
deteriorated in the controls (66±3% vs 54±4%	 in	 AAV6-miR-199a and AAV6-Control 
groups, 28 days after treatment respectively, P<0.05	Figure 8 A). Similarly, there was a 
statistically significant difference between the two groups in LV stroke volume, also 
indicative of improvement in global contractile function (50±3.7% vs 40±1.5% at 28 
days, P<0.05; Figure 8 B). Both LV end-systolic and end-diastolic volumes tended to 
deteriorate in the infarcted animals, indicating remodelling with cardiac dilatation, 
however there was a statistically significant preservation of end-systolic volume in the 
AAV6-miR-199a group (LVESV 30±2.7% vs 42±3.5% at 28 days; LVEDV 69±8% vs 
87±11% at 28 days; P<0.05; Figure 8 C and D respectively).  
In addition to global cardiac function, CMRI was also used to assess regional/segmental 
contractility, which appeared of particular importance since AAVs were injected 
selectively along the border zone of MI, with the potential to underestimate their local 
effect using global contractility indexes exclusively. Regional function was assessed by 
MRI-tagging (Figure 9 A) to measure circumferential strain (ECC) and radial strain (ERR). 
These two indexes were evaluated along short-axis LV slices (basal, middle, and apical) 
divided into 8 equal circumferential segments, starting from the line of attachment of 
the right ventricle to the LV, which served as the reference point (Figure 9 B). The 
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values for ERR and ECC, obtained for each segment, were plotted to generate curves 
(Figure 9 C and D respectively) and, subsequently, the area under the curve (AUC) was 
calculated to integrate all the values along the LV circumference (scheme in Figure 9 E 
and values in Figure 9 F and G respectively). The segmental analysis indicated that, at 
30 days after MI, both  ECC and ERR, were significantly lower in the AAV6-Control MI 
group, compared to sham operated pigs, however they were almost completely 
recovered in the AAV6-miR-199a group, especially the ECC (ERR 540±60 vs 180±50; ECC -
250±30 vs 160±27 ; P<0.01; Figure 9 F and G respectively). Percent of systolic LV wall 
thickening (LVWT) was also assessed, with no need for tagging, using the same 
approach, obtaining very similar results (LVWT 550±70 vs 200±90; P<0.01; Figure 9 H 
and I).  
Finally, the ‘first-pass’ method based on image acquisitions immediately after bolus 
injection of gadolinium was employed to semi-quantitatively assess myocardial 
perfusion. No significant difference was detected between the two groups of infarcted 
pigs in any LV region and at any time point (data not shown). 
Taken together, these findings indicate that the detected morphological improvements 
were paralleled by significant recovery of global and regional contractile function. 
 
3.2.5 AAV6-miR-199a induces CMs proliferation 
 
We wanted to understand the molecular correlates of reduced infarct size and 
improved cardiac function of the AAV6-miR-199a-treated pigs. Our previous work 
showed that delivery of the same vector, using the AAV9 capsid, to infarcted hearts in 
mice induced in vivo cardiomyocyte proliferation and cardiac regeneration [82]. To test 
the pro-proliferative effect in pig, we injected AAV6-Control and AAV6-miR-199a in an 
additional set of animals (n=3 per group), subjected to ischemia reperfusion using the 
same protocol as above. These animals received 10 intramuscular injection of BrdU 
every day from day 2 to day 12 after MI and then sacrificed (Figure 10 A). In the infarct 
border zone of the animals treated with AAV6-miR-199a we observed the presence of 
large cells with cardiomyocyte morphology clearly positive for the proliferation marker 
Ki-67 (7.6±0.5% of cardiomyocyte in the injected area compared to 1.9±0.2% in control 
animals; P<0.05 (Figure 11 A and B). This was consistent with increase in 
cardiomyocytes with BrdU-positive nuclei (an S-phase marker; 8.9±1.1% vs. 2.2±0.3%; 
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P<0.05 (Figure 10 B and C), staining for phosphorylated histone H3 (pH3, a marker of 
passage through G2/M; 0.75±0.05% vs. 0.19±0.02%; P<0.05 (Figure 11 E and F) and, 
occasionally in only the miR-199a group, Aurora B kinase localization in mid-bodies, 
marking cells undergoing karyokinesis (Figure 11 M ). 
Another set of animals was submitted to the same infarction protocol as above and 
treated with AAV6-Control and AAV6-miR-199a (n=3 per group), however these animals 
were injected with BrdU from day 20 to day 30 to assess proliferation at 1 month 
(Figure 10 D). At this time point, analysis of Ki-67 and pH3 revealed that proliferation 
was almost extinguished (Figure 11 C, D and G and H respectively); a few 
cardiomyocytes in the AAV-miR-199a group were still positive for BrdU (8.8±0.9% vs. 
3.5±0.5%; P<0.05), most likely indicative of still ongoing duplication in the 10 days prior 
to sacrifice (Figure 10 E and F). Figure 11 I and L show the percentages of Ki67- and 
pH3-positive cardiomyocytes, respectively, at 12 and 30 days after infarction. Both 
measurements provide an indication of the current proliferation activity at the time of 
analysis and are concordant in showing quenching of proliferation at one month after 
treatment.  
These findings collectively indicate that expression of miR-199a after MI markedly 
boosts endogenous CM proliferation. 
 
3.2.6 Histological and molecular analysis of infarcted hearts treated with AAV6-miR-
199a 	
We wanted to assess the histological and molecular correlates of increased CM 
proliferation in the animals treated with AAV6-miR-199a. Concordant with the CMRI 
data, we observed that, at 28 days after MI and vector injection, there was a significant 
reduction of the fibrotic area in the infarcted region (representative images from three 
different animals at various magnifications and quantification in Figure 12 A and B). In 
the infarct border zone, in which the vectors had been injected, increased proliferation 
in the AAV6-miR-199a animals was paralleled by the presence of a vast number of cells 
with CM morphology expressing GATA4, a transcription factor essential for cardiac 
development and known to be expressed de novo during zebrafish heart regeneration 
[172]. GATA4 normally localizes in the nucleus where it promotes transcription of 
cardiac specific genes; however, cytoplasmic expression is also known to occur during 
embryonic development, at day 9.5 in the mouse [173]. In the animals treated with 
	 62	
AAV6-miR-199a, a relatively large number of CMs showed GATA4 cytoplasmic 
localization at both 12 and 30 days after MI and vector injection (2.5±0.5% of 
cytoplasmic GATA4 CMs vs. 0.5±0.5% in treated and control animals at day 12, 
respectively; 1.9±0.4% of cytoplasmic GATA4 CMs vs. 0.4±0.3% in treated and control 
animals at day 30, respectively; P<0.05; Figure 13 A-D).  
There were no significant differences in the levels of other markers of muscle and 
vascular pathology in the miR-199a-treated animals compared to infarcted controls, 
including desmin (which is essential for maintaining structural and functional integrity 
of myocytes [174]	and was expressed at normally high levels, Figure 13 E), myogenin 
(which coordinates skeletal myogenesis and repair [175] and was not expressed Figure 
13 F), endothelin-B receptor (which selectively stained arterioles' smooth muscle cells	
[176], Figure 13 G) and Wilms' tumor protein 1 [177] (Wt1, which was expressed at low 
levels in the vascular endothelium but not in myocytes Figure 13 H).  
Vessel density was assessed by staining endothelial cells with fluorescinated lectin and 
arterioles with an anti-α-SMA antibody. No significant difference was detected in vessel 
morphology and capillary density compared to cardiomyocytes at either 12 or 30 days 
after treatment between the two infarcted and treated groups (data not shown). 
Finally, we analysed the hypertrophic response after MI. In infarcted pigs treated with 
AAV6-Control both atrial natriuretic peptide (ANP) and bone natriuretic peptide (BNP) 
were increased at both 12 days and 1 month after infarction, while this response was 
blunted in the animals treated with AAV6-miR-199a (Figure 15 E, F and C and D 
respectively). Consistent with preservation of cardiac function, the ratio between 
transcripts for the adult α- and the fetal β-myosin heavy chains was preserved in the 
AAV6-miR-199a treated animals at both time points (Figure 15 A and B). Preservation 
from maladaptive hypertrophy by miR-199a was also observed at 1 month after 
treatment both macroscopically post-mortem (representative animal shown in (Figure 
14 C) and at the histological levels, by quantifying CM area after staining heart 
histological section with lectin WGA (wheat germ agglutinin) or periodic-acid-Schiff 
(PAS). This measurement revealed reduction of the hypertrophic response in the AAV6-
miR-199a-treated animals compared to controls (Figure 14 A and B). 
When analysed collectively, these findings are concordant in showing that increased 
cardiac regeneration in the miR-199a animals was paralleled by the expression of the 
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developmental marker GATA4 in the absence of overt markers of cardiac or vascular 
pathology.   
 
3.2.7 Sudden death and pathological findings in the longer term in pigs treated with 
AAV6-miR-199a despite morphological and functional recovery 	
A subset of infarcted animals treated with AAV6-Control (n=6) and AAV6-miR-199a 
(n=7) was followed up for a longer time period. In one of the pigs analysed at 8 weeks, 
CMRI continued to show persistent beneficial effects on cardiac morphology and 
function, with progressive reduction of cardiac scar (LGE-CMRI images showing 4 cross-
sectional planes at 1, 4 and 8 weeks in this animal and in a representative AAV6-Control 
animal shown in Figure 16 A). However, despite these persistent beneficial effects on 
post-MI scar extension and ventricular function, 6 out of 7 pigs in the of AAV6-miR-199a 
group died from sudden death in the absence of preceding clinical signs during weeks 
7-8. Their mortality was significantly higher compared to AAV6-Control, in which only 
one death was recorded in the first 8 weeks  (Figure 16 B). In one of the pigs treated 
with AAV6-miR-199a, it was possible to record, thanks to a subcutaneously implanted 
recorder (Reveal, Medtronic), that its sudden death was due a tachyarrhythmia evolving 
into ventricular fibrillation (Figure 17).  
Cardiac tissue from the pig which survived at 8 weeks and from the other pigs which 
died at 7-8 weeks was retrieved for histological analysis (Figure 16 C). Careful 
examination of haematoxylin-eosin-stained tissue sections revealed, in three of the pigs 
injected with miR-199a, the occasional presence of small clusters of cells infiltrating the 
myocardium. These cells were negative for the leukocyte common antigen CD45 
(excluding their myeloid or lymphoid derivation as inflammatory cells) and CD34 (blast 
cells of hematopoietic origin or activated endothelium) and were highly proliferating, as 
concluded from virtually complete positivity for Ki-67 expression. Cells were also 
negative for markers of muscle differentiation, including desmin (identifying myogenic 
cells of cardiac, smooth and striated muscle), sarcomeric α-actinin (which labels Z lines 
in the cardiac and skeletal muscle sarcomere) and HHF35 (a monoclonal antibody 
recognizing muscle-specific α- and γ-actin); cells were also negative for Wt1 (marking 
several malignancies). The infiltrating cells, however, were positive for a few antigens 
known to be expressed during early myogenic development, including two main 
myogenic transcription factors (GATA4, which is critical for proper mammalian cardiac 
	 64	
development), and myogenin (the reactivation of which characterizes 
rhabdomyosarcoma cells) as well as the calmodulin-binding protein caldesmon (which 
regulates smooth muscle contraction and is expressed at high levels in leiomyoma and 
leiomyosarcoma) and the endothelin-B receptor, which is expressed in smooth muscle 
cells. Collectively, therefore, these cells appear to show markers of early muscular 
differentiation. 
Even if these few clusters of cells found in AAV6-miR-199a hearts were highly 
proliferating and appeared to have an infiltrating phenotype, no other pathological cell 
expansion was found in other organs, nor abnormal cell growth or tumours were found 
during necropsy in any of the treated animals. 	
PART 3 – DELIVERY OF microRNA MIMICS IN MOUSE HEARTS 
 
AAV vectors are excellent tools for myocardial gene transfer in terms of capacity to 
delivery their genes to post-mitotic cells selectively, including cardiomyocytes. 
However, these vectors persist, in the form of episomal, concatamerized, nucler DNA, 
for indefinite periods of time in the transduced cells, virtually coinciding with the life of 
the animals. This characteristics is obviously desirable for gene therapy of inherited 
disorders, however becomes problematic for the delivery of a pro-proliferative factors, 
as the long-term results observed in pigs also highlighted. 
As an alternative to the use of viral vectors, we wanted to evaluate the efficacy of 
synthetic miRNA mimics at inducing myocardial repair after single intracardiac injection 
using synthetic lipid formulations as delivery tool.  
 
3.3.1 Commercial lipid formulations to vehicle miR-199a to the heart 	
The clinical translation of microRNA treatment for cardiac regeneration will necessarily 
entail the development of an administration protocol that combines the best efficacy 
with the highest standards of safety. With this ultimate goal in mind, we designed a set 
of experiments to test and compare the performance of different commercial lipid 
transfecting agents to vehicle microRNA mimics to the heart.  We selected 5 different 
commercial lipid formulations: Oligofectamine, Lipofectamine 2000, Xtreme Gene and 
INTERFERin, and assayed their efficacy to transfect an siRNA targeting the Ubc gene in 
the ubiquitination cascade in primary neonatal rat cardiomyocytes. This gene is 
	 65	
essential for cell viability	[178], including that of cardiomyocytes [82]. We comparatively 
evaluated transfection efficiency, measured as the percentage of sarcomeric alpha 
actinin-positive cells dying upon treatment (Figure 18 A) or by measuring ATP 
production as surrogate for survival (Figure 18 B); the latter measurement was also 
informative for all the cell types present in the primary culture, including, besides 
cardiomyocytes also fibroblasts and endothelial cells, and also took into account the 
overall toxicity of the vehicle alone. We found that lipofectamine RNAiMax had the 
highest transfection efficiency in neonatal rat cardiomyocytes, evaluated with both 
techniques (around 80% of transfected cells), among the tested reagents. 
Next we tested the three lipid formulations that were most effective in vitro, plus one 
additional lipid reported to work in vivo in other tissues (Invivofectamine), for their 
ability to deliver the miR-199a-3p mimic in vivo in the heart of 2-month old CD31 
female mice (n=6 per group). Two days after intracardiac injections of the different RNA-
lipid complexes, we evaluated the levels of miR-199a-3p expression in the anterior wall 
of left ventricles as well as the expression of genes that are known be targeted directly 
by miR-199a, Homer1 and Clic5, which were used to assess microRNA function. With all 
lipid formulations, but most remarkably with Lipofectamine 2000 and Lipofectamine 
RNAiMax, we observed a consistent and significant increase in the amount of miR-199a-
3p, which was over 250 folds the endogenous one (Figure 18 C), paralleled by a 
decrease in the mRNAs of Homer1 and Clic5 ((P<0.05; Figure 18 D). This indicated 
effective transfection in vivo using the developed protocol. 
Finally, we assessed the microRNA extracardiac dissemination in mice injected with 
Lipofectamine RNAiMax/miR-199a-3p. Over several organs examined, only liver and 
kidney displayed a significant upregulation of miR-199a-3p, 4.7-fold and 8.3 fold over 
the endogenous levels respectively (P<0.05 in both cases; Figure 18 E). 
Together, these results indicated that miR-199a-3p in vivo transfection can be achieved 
by a single intracardiac injection exploiting cationic lipid formulations. 
Lipofectamine RNAiMax was chosen for all the subsequent in vivo studies described 
below.  
 
3.3.2 MicroRNA persistence after intracardiac injection 	
To assess the potential of microRNA mimic in pro-regenerative therapy, next we 
evaluated microRNA persistence after intracardiac injection, in mice, of complexes of 
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Lipofectamine RNAiMax/miR-199a-3p or Lipofectamine RNAiMax/cel-miR-67 
(Caenorhabditis elegans miR-67, a nontargeting mimic used as a control; n=6 per group). 
Levels of the microRNA mimics, as quantified by qRT-PCR from the left ventricle free 
wall, were very high, 296.0±21.9-fold over control, at 2 days after intracardiac injection 
(Figure 19 B) and progressively decreased over time (37.0±4.0-fold at 4 days, 7.6±1.1-
fold at 8 days and 2.2±0.2-fold at 12 days), until disappearing at 20 days from treatment 
(P<0.05 at all time points; Figure 19 B). 
At 2 and 4 days after injection (Figures 19 C and D respectively), persistence of the 
mimic was associated with the downregulation of the microRNA targets mRNA Homer1 
and Clic5, thus indicating that the injected miRNA was biologically active. However, 
Homer1 and Clic5 mRNA levels were no more significantly downregulated at 12 (Figure 
19 E) and 20 days (Figure 19 F) after mimic intracardiac injection.		
Collectively, these results indicate that, after direct intramyocardial injection, mi-199a 
mimic exert a functional effect lasting several days. 
 
3.3.3 MiR-199a-3p mimic single intracardiac injection improves cardiac function after 
MI  	
The experiments described above demonstrated that it was possible to achieve efficient 
in vivo microRNA mimic transfection, which lasted for several days. Thus we wanted to 
evaluate the efficacy of mimic injection after MI.  
After permanent ligation of the left anterior descending coronary artery, 2 month-old 
CD1 female mice received 2.7 μg miR-199a-3p (n=20) or cel-miR-67 (n=13) complexed 
with Lipofectamine RNAiMax injected into the surviving peri-infarcted myocardium. 
Five and 3 animals died in cel-miR-67 and miR-199a-3p groups, respectively, within the 
first 20 days (Figure 20 A). 
Echocardiography measurements monitored cardiac function of the surviving animals, 
displaying comparable heart rate, up to 8 weeks from treatment. Cel-miR-67 injected 
animals displayed a progressive impairment of LVEF from week 1 to week 8, (24±8.1% at 
week 8) (Figure 20 B). In contrast, while LVEF of miR-199a-3p-injected animals was 
comparable to that of controls during the first 2 weeks, from this time point it remained 
constant up to 8 weeks (LVEF at week 8 was 37.5±4.5%; P<0.05 vs. control) (Figure 20 
B). 
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In a consistent manner, analysis of other cardiac function parameters obtained by 
echocardiography, including LV fractional shortening (Figure 20 C) and LV anterior wall 
(Figure 21 A and B) and septum thickness showed a similar trend (Figure 21 C). Left 
ventricle systolic internal diameter was not increased by miR-199a-3p treatment at all 
the time-points analysed (Figure 20 D) indicating that there was no further cardiac 
dilatation upon mimic injection. In addition, animals in the miR-199a-3p group 
displayed no further hypertrophic response of cardiomyocytes after MI compared to 
control animals (Figure 22 A and B). 
At the moment of sacrifice, 8 weeks after MI, infarct size measured by Masson’s tricrome 
staining was significantly reduced in miR-199a-3p treated animal (28±4.8% of the LV in 
control animals versus 18±3.0% in the miR-199a-3p-treated group (P<0.05; Figure 23 A 
and B). 
Some animals were injected with ethynyl-29-deoxy-uridine (EdU), a thymidine analogue 
(n=6 per treatment), every second day from day 1 to day 12 after MI and miRNA mimic 
treatment to assess cell passage through the S phase. Animals treated with miR-199a-3p 
showed a 2.5-fold increase in the number of cardiomyocytes that had incorporated EdU 
(Figure 23 C and D). Likewise, immunofluorescence for the phosphorylation of histone 
3 on serine 10, a marker of late G2/M, showed increase positivity at day 4 after MI and 
miR-199a-3p treatment (Figure 23 E and F), as was the number of cardiomyocytes 
positive for Aurora B, which showed nuclear but also midbody localization, indicating 
passage through mitosis (Figure 23 G and H). 
Finally, miR-199a-3p treatment had no effect on cardiomyocyte protection from cell 
death as analyzed by terminal de-oxynucleotidyl transferase dUTP nick end labeling 
staining two days after MI and mimic injection (Figure 23 I and L). 
Collectively, these results demonstrate that transfection of miR-199a-3p mimic leads to 
cardiac repair by stimulating cardiomyocyte proliferation and therefore preserves 
cardiac function after MI.  
 
PART 4 – CHEMICAL MODIFICATIONS OF miR-199a-3p TO INCREASE STABILITY AND 
EFFICACY 	
3.4 miR-199a-3p mimic chemical modification to increase its stability 	
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Once injected in vivo, microRNAs are subject to degradation by abundant ribonucleases 
present in the blood and extracellular matrix. We therefore tested five chemical 
modifications of miR-199a-3p to assess whether they increased their stability while 
preserving efficacy. In addition to the original mimic formulation purchased from 
Dharmacon, which was used for all the other experiments described in this thesis so far 
(Figure 24 A), the following modified mimics were obtained: 
• E1: LNA and phosphorothioate stabilization at 5’ and 3’;  
• E2: LNA plus a phosphorothioate stabilization at 5’ and 3 and a 2’-O-Me 
modification on the passenger strand;  
• E3: 2-F mimic plus a phosphorothioate stabilization and a 2’-O-Me 
modification on the passenger strand (design A);  
• E4. 2-F mimic plus phosphorothioate stabilization and 2’-O-Me modification 
on the passenger (design B); 
• I: 2’-O-Me modification on the driver strand, in order for the passenger to 
become inactivated and not enter RISC; 
Mimics E1, E2, E3 and E4 were provided by Exiqon according to a proprietary design; 
differences among design A and B of sequences E3 and E4 are not disclosed by the 
vendor. Mimic I was provided to us by Integrated DNA Technologies (IDT) (Figure 24 A). 
These mimics were first tested in neonatal rat cardiomyocytes by assessing the 
stimulation of proliferation rate by EdU incorporation at 72 hour after transfection. All 
mimics were able to increase cardiomyocyte proliferation at least as efficiently as the 
standard formulation from Dharmacon (Figure 24 B and C). Accordingly, all mimics also 
decreased the mRNAs of the target genes Homer and Clic5 (Figure 24 D and E). The top 
scoring molecule in this comparison was mimic E3 from Exiqon.  
We further evaluated stability and persistence of mimics E3 (Exiqon), I (IDT) and the 
Dharmacon mimic after direct intracardiac injection in adult mice by quantifying their 
relative levels at days 2, 8 and 21 after injection (n=6 for each group; cel-miR-67 injected 
mice served as control; Figure 24 A-C). At day 2, mimic E3 was upregulated 800 folds 
over control, while I and Dharmacon mimic levels were approximately 200 folds over 
control (Figure 25 A). At day 21, however, the levels of mimic I were significantly 
(approximately 6 fold) higher than those of the other two mimics (Figure 25 C). The 
levels of two miR-199a-3p direct gene mRNAs, Homer and Clic5, were downregulated at 
2 and 8 days but not at 21 days after injection (Figure 25 D-I). 
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Mimic I, the levels of which were the highest among the mimics tested at 21 days, were 
further assessed in mice subject to MI by the permanent ligation of the left anterior 
descending coronary artery. After MI induction and mimic intracardiac injection (cel-
miR-67 served as control, n=6 per group), functional parameters were followed by 
echocardiography up to 8 weeks. While cel-miR-67-injected mice displayed a 
progressive impairment in heart function, as expected, LVEF in the two miR-199a-3p 
groups remained stable up to 8 weeks after MI (at 8 weeks:  miR-199a-3p Dharmacon 
LVEF 29±4.5%; miR-199a-3p I LVEF 28±5.3%) (Figure 26 A). Left ventricle ejection 
fraction and LV telediastolic volume did not show any significant difference between 
miR-199a-3p Dharmacon and miR-199a-3p I groups at all the time points analysed 
(Figure 26 A and C). However, LV anterior wall was increased, even if not significantly, 
in miR-199a-3p I injected mice (Figure 26 B). 
Together, these results indicate that miR-199a-3p I is the more stable than miR-199a-3p 
Dharmacon when injected in vivo. Nevertheless, miR-199a-3p I injection after MI exerts 
the same beneficial effect on heart function as that obtained using miR-199a-3p from 
Dharmacon.
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4. DISCUSSION  
Achieving functional regeneration of damaged hearts represents a long sought goal of 
clinical and experimental research. Following the general disappointment of 
approaches based on the implantation of stem cells of various derivation, which were 
shown to essential act through paracrine secretion of beneficial factors rather than 
generation of contractile myocardium (see Introduction), the identification of a normal 
turnover of cardiac myocytes during the adult life has opened the perspective of 
achieving cardiac regeneration through the stimulation of already existing 
cardiomyocytes to enter the cell cycle. Studies based on the incorporation of 
atmospheric C14 in humans [11] or imaging mass spectrometry in mice [7] are 
concordant in showing that approximately 1% cardiomyocytes are generated every 
year, a percentage that increases 2-3 times after MI. These observations not only show 
that the heart is not a completely post-mitotic organ, but also offer a rationale for 
innovative therapies aimed at stimulating this small, but existing replicative potential. 
Previous work from the Molecular Medicine Laboratory at the ICGEB in Trieste has 
shown that a series of microRNAs are capable to stimulate neonatal cardiac myocytes 
from rats and mice to proliferate and that AAV vectors expressing two of these miRNAs 
(miR-590 and miR-199a) are effective at stimulating cardiac repair after MI in vivo [82]. 
The use of miRNAs as genetic tools to stimulate cardiac proliferation is of particular 
interest, in light of the capacity of these molecules to regulate expression of multiple 
genes simultaneously. In contrast to the overexpression of individual cDNAs or the 
downregulation of individual genes by RNAi or knock-out technologies, the use of 
miRNAs offers the advantage that these molecules are pleiotropic in their action, a 
property appearing desirable in light of awakening a complex process such as that of 
cardiomyocyte proliferation. For example, work carried out in the laboratory over the 
last years has shown that transduction of a single gene, such as the powerful inducer of 
cardiomyocyte proliferation during the embryonic life Notch1, is indeed capable to 
stimulate proliferation of cardiomyocytes at birth, but is inactive in doing so in adult 
cells [179]. MicroRNAs, in contrast, by targeting multiple transcripts simultaneously, are 
more likely to modulate biological pathways or functions and thus, in principle, more 
likely to be effective than single genes. This property, however, has the drawback that 
the effect of miRNAs is more pleiotropic than that of individual genes, a concept that 
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well applies to the long term, deleterious effect of miR-199a expression observed in 
pigs, which will be described later.  
Based on the previous results that had led to the identification of miRNAs promoting 
proliferation of rodent cardiomyocytes, the overall objective of this Thesis has been to 
explore the potential for clinical translation of a miRNA-based approach to achieve 
cardiac repair after myocardial infarction. The proof of safety and efficacy of a new drug 
or therapeutic treatment in large animal models is a fundamental step toward the 
approval of its use in a clinical experimentation. This has been the specific subject of 
this study. 
 
4.1. microRNA candidate selection to induce human cardiomyocyte proliferation 	
To identify the microRNA candidates potentially able to induce adult human 
cardiomyocyte proliferation, eight human microRNAs selected from the original high-
throughput screening performed in neonatal rodent cells [82], were tested in 
cardiomyocytes derived from human ES- and iPS-cells for their capability in boosting 
cell-cycle reentry (data not shown). However, the procedures for differentiating 
cardiomyocytes from ES- and iPS-cells generate cardiomyocytes that are rather 
immature and resemble early embryonic cardiomyocytes. In the experiments 
performed with these cardiomyocytes, for example, the most effective miRNAs were 
those belonging to the miR-302/miR-367 cluster, known to be overexpressed in ES cells 
and be required to maintain their undifferentiated phenotype [180] – data not shown. 
This does not necessarily reflect the capacity of these miRNAs to act on more 
differentiated cardiomyocytes. 
 
For this reason, we decided to test the cherry-picked eight microRNAs in primary 
cardiomyocytes cultures established from 17-22-week-old-gestation human abortive 
fetuses. These cells, although still not fully differentiated, appear to represent a more 
reliable and robust model for human cardiomyocytes. Our experiments revealed that 
several of the selected microRNAs were able to induce DNA synthesis and G2/M phase 
transition measured as EdU incorporation (Figure 4) and phospho-histone 3 positive 
immunofluorescence (data not shown) respectively. Of note, the effect was much 
stronger when the microRNAs were delivered as synthetic mimics, rather then as 
transgenes expressed by AAV vectors, even after efficient viral  transduction (Figure 4C). 
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Some of the microRNAs tested had very modest effect on cardiomyocyte proliferation, 
such as miR-18a*, or miR-30e* and miR-590-3p; of note, miR-590, when delivered as 
precursor using an AAV vector, was even detrimental to cell proliferation, suggesting 
that the 5p strand has opposite effects and might compete with the 3p for RISC 
incorporation and target mRNA inhibition. This is a testable hypothesis for future 
investigational work. 
MicroRNA-33b* and miR-302d were able to induce 12- and 10- fold cardiomyocyte 
proliferation increase over control (cel-miR-67) respectively when delivered as synthetic 
mimics. However, miR-33b* has a controversial role in cancer expansion [181, 182], 
while miR-302d long-term expression is already known to induce cardiomyocyte 
dedifferentiation and dysfunction [89], thus limiting their potential use for human 
therapeutic applications. MicroRNA-199a-3p, miR-1248-3p, and miR-1825-3p mimics 
boosted cardiomyocyte proliferation approximately 5-folds compared to control. 
However, the last two miRNAs are absent in mouse, rat and pig, thus making their 
characterization and definition of the mechanism of action difficult to study. On the 
contrary, the miR-199a sequence is fully conserved in human, mouse, rat and pig, and 
the role of this miRNA in many different biological processes, including proliferation, 
metabolism, hypertrophy, autophagy and cell death, has been extensively studied and 
elucidated (see Introduction). In light of these considerations, miR-199a-3p was selected 
for further safety and efficacy studies in a large animal model.  
 
4.2. AAV6-miR-199a intra-cardiac injection after myocardial infarction in pigs 
improves cardiac morphology and function 	
The study we conducted to prove efficacy of miR-199a in pigs entailed the induction of 
myocardial infarction by a 90-minute occlusion of the second branch of left anterior 
descending coronary artery (LAD) in 3 to 4-month-old farm pigs, and the subsequent 
delivery of an AAV6 vector carrying the miR-199a precursor DNA by 20 direct injections 
into the infarct border zone. Animal cardiac function and infarct size were followed by 
late gadolinium-enhancement cardiac magnetic resonance 2 and 30 days after surgery.  
Imaging analysis performed at day 2 after infarction by cMRI showed no difference in 
the extension of the myocardial damage between controls (AAV6-Control) and AAV6-
miR-199a-treated animals. On the contrary, cMRI at one week after surgery already 
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highlighted a beneficial effect of the microRNA treatment (data not shown), which 
turned to a significant reduction of the infarct core region after one month.  
Analysis of the individual animals over time by cMRI was consistent with the conclusion 
that AAV6-miR-199a stimulated a regenerative process progressively healing the 
damaged myocardium.  Consistent with this morphological conclusion, cMRI performed 
at one month after MI and vector delivery showed significant improvement of ejection 
fraction and other functional parameters in the AAV6-miR-199a-treated animals, 
indicating better global cardiac function. Both global and regional contractility resulted 
significantly improved at one month after treatment, the latter measured by assessing  
circumferential and radial strain by tagging MRI. Of note, cMRI currently represents the 
gold standard for the objective, unbiased evaluation of cardiac function.  
Could myocardial tissue recovery and improved cardiac function be ascribed to an 
effect of AAV6-miR-199a on cardiomyocyte survival after MI? Several considerations 
appear to be against this possibility. First, our previous work has explored whether the 
most effective pro-proliferative miRNAs that our screening identified, including miR-
199a-3p, exert an anti-apoptotic effect, but failed to identify such activity [82]. In the 
infarcted pigs sacrificed at 12 days for the BrdU incorporation studies in this work we 
extensively searched for TUNEL-positive cardiomyocytes, without finding any evidence 
of protection from apoptosis in the AAV6-miR-199a-injected animals. Consistent with 
this result, protection from cardiomyocyte death was neither detected in mice injected 
with miR-199a-3p mimics, even when the analysis was performed at the more 
informative time point of 2 days after infarction detected [170]. 
Second, analysis of the extent of edema and measurement of infarct mass and size at 2 
days after MI are concordant in showing similar extent of myocardial damage. Should 
AAV6-miR-199a be effective in preventing cardiomyocyte loss immediately after 
infarction, its effect would be likely of having been observed also at this early time 
point. In this respect, it is worth mentioning that, in normal tissue, AAV vectors are well 
known to take several days to reach maximum transgene expression [183]. However, in 
damaged tissues, such as the infarcted heart or skeletal muscle, expression initiates few 
hours after cell infection and raises rapidly [184]. 
Third, the increase in cardiac mass observed by cMRI in the AAV6-miR-199a animals was 
paralleled by the appearance of a large number of BrdU-positive and Ki-67-positive cells 
in the infarct border zone, the same regions where the vectors were injected. These cells 
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not only entered the cell cycle (Ki-67) and synthesized new DNA (BrdU), but also 
traveled through G2/M (positivity for phosphorylated H3) and, more occasionally, 
showed localization of the Aurora B kinase in midbodies, a marker of cell division. Based 
on these considerations, it appears plausible to conclude that the reduced infarct size 
and improved myocardial function observed in the AAV6-miR-199a animals might be 
ascribed to a true regenerative process. 
When analyzing cardiomyocyte proliferation in the miR-199a animals, we observed that 
the proliferative activity of cardiomyocytes was relatively high at 12 days after MI and 
vector administration, while it was significantly quenched at one month. At this latter 
time point, there was still a significantly increased number of BrdU cells, however this 
most likely reflected incorporation of this analogue in the 10 days prior to sacrifice, 
when the animals were administered with the drug, since analysis of Ki-67 by 
immunohistochemistry and phospho-H3 by immunofluorescence revealed no 
differences in the AAV6-miR-199a group compared to the control one. This result is of 
potential biological interest, since it might indicate that the stimulus exerted by miR-
199a expression might be essential but not sufficient to drive cardiomyocyte 
proliferation, which would instead also require a proper permissive environment, for 
example generated by the secretion of still unidentified growth factors from the 
damaged myocardium (which would occur immediately after damage but not one 
month later). This conclusion also appears consistent with our observation that the 
injection of AAV vectors expressing miR-199a in un-infarcted, normal both mouse and 
in pig heart exerts no apparent effect (data not shown). 
In our study, we decided to express miR-199a from its precursor DNA for practical 
reasons and taking advantage of the high efficiency of AAV vectors in the myocardium. 
In this experimental setting, both microRNA strands are expressed at high levels (data 
not shown) and, consequently, we could expect the induction of additional effects 
specific for miR-199a-5p. In particular, this miRNA was shown to induce a hypertrophic 
response in rodents [113, 114] [112]. In our study, however, we were unable to detect 
obvious cardiomyocyte hypertrophy induced by the miRNA, especially since all pigs 
were infarcted and thus subject to hypertrophy compensatory to loss of cardiac 
function. Certainly no additive hypertrophic effects of the miRNA were observed, since, 
on the contrary, preservation of cardiac function instead reduced hypertrophy in the 
miR-199a-treated animals, as concluded from the analysis of cardiomyocyte cross-
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sectional area. It is also possible that the target genes related to hypertrophic response 
of the 5p strand might not be conserved in pigs.  
In accordance with the favourable tissue remodelling promoted by miR-199a, the ANP 
and BNP peptides measured in patients’ sera as diagnostic and prognostic markers of 
heart failure [185], were down-regulated in the treated animals at all the time points 
analysed. Pathological cardiac hypertrophy and heart failure are also characterized by a 
reduction in the expression of Myh6 (alpha), the myosin isoform that hydrolyses ATP 
three times faster than Myh7 (beta) [186]. Consistently, in our experimental settings we 
observed that AAV6-Control animals had a reduced Myh6/ Myh7 ratio compared to 
sham-treated animals, while AAV6-miR-199a injected pigs showed increased levels 
Myh6, consistent with improved contractility and reduced myocardial damage. 
In our previous work, we demonstrated that miR-199a directly targets the Homer1, Hopx 
and Clic5 mRNAs in mice [82] and that the simultaneous silencing of these genes 
increases neonatal mouse cardiomyocyte proliferation as strong as the microRNA itself 
(data not shown). Unfortunately, the microRNA target site is not conserved in the 3-
UTRs of these genes’ mRNAs in pigs, suggesting that miR-199a may exert its function by 
targeting other proteins in the same pathways, or different proteins that have the same 
function, or the same genes but through target sites in mRNA regions other than the 
3’UTR.  
In a parallel study, we also identified Cofilin2, Taok1 and β-trc as additional miR-199a 
direct targets in rodents. The downregulation of these proteins activates YAP, the final 
effector of the Hippo pathway, which, once in the nucleus, promotes the transcription 
of genes necessary cell proliferation [187]. In these cases, the microRNA target sites are 
conserved in the pig mRNA 3-UTRs for all the three genes and, we consistently could 
measure downregulation of Taok1 and β-trc (but not Cofilin2), mRNAs in AAV6-miR-
199a treated pigs (data not shown).  
A most remarkable finding at both 12 and 30 days after AAV6-miR-199a administration 
to infarcted pig, was the appearance, in the infarct border zone, of a remarkable number 
of GATA4-positive cells, suggestive of cardiomyocyte de-differentiation. This 
transcription factor regulates the expression of genes involved in embryogenesis and 
myocardial differentiation. In adult and neonatal cardiomyocytes the factor is present 
and active in the nucleus; however, during embryonic life, it can also be found in the 
cytoplasm [173]. Surprisingly, after MI in pig myocardium, a significant number of 
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cardiomyocytes showed marked cytoplasmic localization of GATA4. This observation is 
consistent with the possibility that the expression of miR-199a, along with proliferation, 
might also induce de-differentiation of cardiomyocytes, a process known to accompany 
cardiac regeneration in zebrafish [172]. 
To the best of our knowledge, this is the first proof of cardiac regeneration and 
consequent improvement in cardiac function obtained by the stimulation of the 
endogenous capacity of cardiomyocyte to proliferate after damage.  
 
4.3. Safety issues related to prolonged miR-199a expression using AAV vectors 	
To evaluate the long-term effect of miR-199a constitutive expression, we include in our 
protocol a number of animals which were left alive after the 1 month time point. 
Despite the progressively smaller scar size and the improved heart function observed by 
cMRI in one of the animals analysed at 60 days after MI and treatment, 6 out of 7 
animals treated with AAV6-miR-199a died between days 45 and 55 of sudden cardiac 
death. Three of these animals had implanted ECG mini-recorders and, in one of them, 
we were able to record the episode of ventricular fibrillation that caused its death.  
The real reason for the ventricular fibrillation, but more in general, for sudden cardiac 
death in our treated animals is still unknown and it will be the object of further 
investigation. In particular, a priority for investigation will be the role of the potential 
downregulation of Ryr2, a predicted target of miR-199a-3p, as well as that of other ion 
channel proteins, especially those involved in ion channel genetic dysfunction 
characterized by ventricular fibrillation and sudden death. In addition, we will also 
explore the presence of a dysfunction of Purkinje fibers, which allow fast propagation of 
action potential and might be the substrate for arrhythmogenic events. The pro-
proliferative effect of miR-199a on Purkinje fibers has been excluded (data not shown), 
but it is not known yet whether miR-199a could interfere on Purkinje fiber function and 
action potential propagation. Of potential interest, however, death in the analysed 
animals was almost synchronized and required over 1.5 months to occur, an 
observation that is more consistent with the expansion of a pathological cell 
population, eventually reaching a critical threshold and exerting an arrhythmogenic 
effect, rather than with the direct effect of the miRNA on cardiac conduction, which 
would have been expected to occur at earlier time points.  
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Histological examination of pig heart tissues indicated that, in two animals which died 
of sudden death and the one which sacrificed at 60 days, there were small clusters of 
cells infiltrating the cardiac tissue. These cells were negative for CD45 and CD34, thus 
excluding their lymphoid and myeloid origin as well as their identity as hematopoietic 
blast or activated endothelial cells. The high positivity in immunohistochemistry for Ki-
67, revealed that these cells had a high proliferation rate. These cell clusters were 
negative for differentiated markers of muscle cells, including desmin and HHF35, while 
expressed markers of undifferentiated cells of muscle origin, among which myogenin, 
caldesmon and GATA4. Thus, these cells appear to possess the phenotypic identity of 
myoblastic cells at the early stages of differentiation. Are these highly proliferating cells 
arising from the prolonged and unregulated miR-199a expression? Most likely yes, 
however not necessarily as a direct product of cardiomyocyte transduction, unless it will 
be formally demonstrated that these cells harbour integrated AAV vectors – integration 
would appear to be a necessary event to explain maintenance of the virus along 
successive cell divisions. Alternatively, these cells might arise as the effect of alterations 
in the microenvironment by cytokines and growth factors produced by cardiomyocytes 
primarily transduced with AAV9-miR-199a.  
Can the infiltrating cells be considered as cancer cells? This is a difficult question to 
answer, since, to the best of our knowledge, no human cardiac tumors bears a 
phenotype resembling the cell clusters we have observed in these animals, neither we 
have attempted to culture these cells ex vivo and prove their tumorigenic potential. 
Whatever their origin and derivation, the expansion of infiltrating cell clusters in the 
heart of animals treated with AAV9-miR-199a might well explain the onset of the fatal 
arrhythmias that caused the deaths of these animals. 
In short, our study overall shows that AAV6-miR-199a delivery improves functional 
parameters and reduces scar size in juvenile pigs by stimulating cardiomyocyte de-
differentiation and cell cycle re-entry. Conversely, its long-term expression causes 
sudden cardiac death. It remains to be understood how the two events are linked. At 
least two possibilities can be envisaged. First, proliferation and de-differentiation are 
the results of the same mechanism of action. Similar to zebrafish [188], cardiomyocytes 
re-entering the cell cycle re-express markers of embryonic development. In this view, 
pathology becomes evidence once expression of the de-differentiating and pro-
proliferating agent (miR-199a in our case) becomes excessive or too prolonged. An 
alternative possibility is that the beneficial effect of AAV6-miR-199a in the short term is 
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due to the prevalent action of miR-199-3p, which has beneficial, pro-proliferative effects 
in rodents and human cells. At longer time points, however, the effects of miR-199-5p 
might instead prevail. This miRNA, indeed, has been shown to exert deleterious activity 
on cardiac function (see Introduction). 
Whichever is the mechanism involved, it appears clear that a therapy based on the 
constitutive expression of miR-199a after AAV-mediated gene delivery is not feasible for 
human translation. However, whichever the mechanisms involved, it also appears clear 
that problems in either cases could be overcome by the use of synthetic miR-199a-3p 
mimics, which would provide strand specificity as well as ensure shorter time effects. 
 
4.4 Single injection of miR-199a-3p mimics with various chemical modifications 
improves cardiac recovery after myocardial infarction in mice  	
MicroRNA mimics are small (miR-199a mimic is around 13 590 Daltons), but highly 
charged molecules (44 negative charges in the case of miR-199a mimic) unable to 
spontaneously pass cell membranes. Therefore, the development of a therapy using 
miRNA mimics requires conjugation of these molecules with a delivery carrier, the most 
effective of which, in the case of negatively charged nucleic acids, are cationic lipids. In 
addition to actively mediating tissue transfection, these agents also can effectively 
shield nucleic acids from endonucleases present in the extracellular environment, 
thereby enhancing their persistence. Thus, in this work we tested different 
commercially available cationic lipid preparations for their ability of delivering 
microRNA mimics in the heart, with or without myocardial infarction.  
Four different cationic lipids were tested in vivo, upon direct intracardiac injection; 
among these, the best results were obtained using those originally designed for in vitro 
experimentation, such as Lipofectamine 2000 and Lipofectamine RNAiMax, whilst 
Invivofectamine, proposed by the manufacturers' for in vivo delivery, showed 
significantly lower efficiency. When a complex between miR-199a-3p and 
Lipofectamine RNAiMax was tested in vivo, we found that a single intracardiac injection 
immediately after MI was sufficient to improve cardiac function, assessed by 
echocardiography up to two months, and to reduce scar size. Additionally, we also 
observed that the injected miR-199a-3p mimic levels in the LV anterior wall were 
detectable by qRT-PCR up to 12 days after injection.  
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In evaluating these findings, it appears important to observe that, different from AAV6 
(pigs) or AAV9 (mice) vectors, which both display selective transduction of 
cardiomyocytes, cationic-lipid-mediated mimic delivery affect all cell types in the heart 
(in particular, cardiac fibroblasts and endothelial cells in addition to cardiomyocytes). 
Thus, we can not formally exclude that the beneficial effects of miR-199a-3p mimic we 
observed might also depend, at least in part, on the effect exerted in other cell types. 
Despite cardiomyocytes represent less than 40% in the heart, however, their volume 
occupies over 90% of the organ. In addition, invaginations of the cardiomyocyte 
sarcolemma to form T-tubules further extends the membrane surface that is available to 
uptake exogenously administered lipoplexes. Thus, it would not appear unreasonable 
to assert that most of the transfected mimics is taken up by cardiomyocytes. Further 
experiments can be designed to address the issue of differential transfection of the 
various cardiac cell types specifically.  
A limitation in the use of lipid-based delivery systems is the potential unwanted 
immune response caused by cell membrane disruption that occurs because of the 
many positive charges of the exogenous lipids [189]. Other delivery agents are available 
that might overcome this limitation, such as dendrimers, polymers (polyethylenimine or 
polylactide-co-glycolide), or polysaccharides as chitosan, which are now under 
extensive investigation. Despite the above-mentioned limitations, however, to date 
lipofectamine-based reagents remain the most efficient and the most used delivery 
system, both in vitro and vivo. 
Our experiments with miR-199a-3p show that, once delivered to the heart, this mimic is 
maintained in an active form up to 12 days after injection and that this time is sufficient, 
for the miRNA, to exert a beneficial effect. Can effectiveness be increased by modifying 
the chemical structure of the miRNA in order to extend its half life?  We tested 4 
different chemical modifications of the synthetic mimic provided by two commercial 
vendors. Two of these mimics increased neonatal rat cardiomyocyte proliferation in 
vitro compared to the original mimic used in all other experiements. One of newly 
modified mimics, in particular, once injected into the LV anterior wall in infarcted mice 
was still present as long as 21 days after surgery. Of interest, however, efficacy of this 
modified mimic in healing the infarcted myocardium did not appear superior to that of 
the original molecule. This finding might indicate that the effect of miRNA therapy is 
exerted in the first few days after infarction, and that prolonged expression is not 
effective. This conclusion is in line with the observation that, in pigs, no further 
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cardiomyocyte proliferation was observed at 1 month after miR-199a delivery, even if 
expression of this miRNA from AAV vectors continued to be robust at this time point. 
Elucidation of the molecular mechanisms determining response of cardiomyocytes to 
the effect of miR-199a-3p will help explaining the reasons why cell response to this 
miRNA becomes exhausted over time.
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FIGURE LEGENDS  	
Figure 1. Therapeutic strategies for heart regeneration and signaling pathways 
involved. 
The heart is commonly considered a post-mitotic organ, unable to replace 
cardiomyocyte loss with new functional cells after ischemic damage. Substitution of 
dead cardiomyocytes is the fundamental condition to re-establish cardiac structural and 
functional integrity. A) In the last decade different research lines have aimed at 
restoring cardiomyocyte loss by transplanting or activating cardiomyocyte progenitors, 
transplanting exogenous ES- or iPS-derived cardiomyocytes, direct reprogramming of 
fibroblast to cardiomyocyte or activating pre-exsisting cardiomyocyte proliferation 
(adapted from [190]. B) Schematic and simplified representation of the major signaling 
pathways involved in cardiomyocyte cell-cycle re-entry.  
 
Figure 2. MiR-199a conservation among species and its mRNA targets. 
 A) Representation of miR-199a-1 and miR-199a-2 precursors. Mature miR-199a-5p and 
miR-199a-3p sequences are in green. B) Mature miR-199a-5p and miR-199a-3p 
sequences are conserved in human, mouse, rat and pig. Their seed sequence is in light 
blue and red respectively. C) Schematic and simplified representation of the major miR-
199a transcriptional regulators and mRNA targets of miR-199a-5p and miR-199a-3p. 
Adapted from [90]. 
 
Figure 3. MicroRNA biogenesis.  	
The scheme represents microRNA biogenesis. This starts in the nucleus, where a pri-
miRNA is transcribed by RNA Polymerase II or III. Subsequently, this pri-miRNA is cleaved 
by the microprocessor complex Drosha-DGCR8, thus generating a pre-miRNA, which is 
then exported into the cytoplasm by Exportin-5. Once in the cytoplasm, Dicer cleaves 
the pre-miRNA hairpin to produce a 20-22-nucleotide long, doublestranded RNA, the 
mature microRNA. Mature, double stranded RNA is loaded with Ago2 into the RISC 
complex, where the functional strand of the microRNA silences specific targets. 
Adapted from [61]. 
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Figure 4. MicroRNA sequences and conservation. 
A) List of human microRNAs tested in human fetal cardiomyocytes, their relative 
sequences in human, mouse, pig and rat and relative accession numbers (miRBase 21).  
 
Figure 5. Identification of the most effective microRNA in inducing heart regeneration 
in human primary cultures.  
A) Human fetal cardiomyocyte isolation workflow. B) Representative images of human 
fetal cardiomyocytes during isolation are shown in the upper panels. Lower panels 
show bright-field (left side) and fluorescence (right side) microscopy images of AAV6-
GFP transduced human fetal cardiomyocytes one day after transduction. C) Schematic 
representation of the experimental procedure carried out to identify the proliferative 
effect of the microRNAs under investigation. D) Representative microscopy images of 
human fetal cardiomyocytes transfected with selected microRNA mimics or mock-
transfected control cells. E) Quantification of human fetal cardiomyocyte proliferation 
72 hours after selected microRNA mimic transfection. The graph represents the 
percentage of EdU-positive cardiomyocytes over the total number of cardiomyocytes. 
Data are mean±SEM of 3 independent experiments; **P<0.01. F) Microscopy images of 
human fetal cardiomyocytes transduced with AAV6 expressing the selected microRNA 
precursors or AAV6-GFP (control). G) Quantification of human fetal cardiomyocyte 
proliferation 72 hours after AAV6 transduction with microRNA precursors or GFP. Data 
are mean±SEM of 3 indipendent experiments; *P<0.05, **P<0.01. Scale bar = 100 μm. 
 
Figure 6. Adeno-associated virus 6 (AAV) is the most effective serotype for porcine 
heart transduction.  
A and B) Graphs representing viral genomes and EGFP mRNA levels, respectively, one 
month after direct intracardiac injection of AAV6, AAV8 and AAV9 carrying the EGFP 
transgene. Data are mean±SEM; n=3 per group; **P<0.01. C, D and E) Representative 
images taken during porcine surgery. After thoracotomy, pericardial sac is removed (C), 
LAD is exposed (D), and its second branch is occluded for 90 minutes. Ten minutes after 
reperfusion, AAV6-Control or AAV6-miR-199a are injected in the infarcted border zone 
(E). F) Schematic representation of pig heart sectioning after sacrifice. G and H) Graphs 
representing miR-199a-3p quantification 12 days and 1 month after infarction and 
vector delivery, respectively. Data are represented as fold over endogenous levels 
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(AAV6-Control injected animals). Data are mean±SEM; n=3 per group for 12 days and 
n=4 and n=5 for AAV6-Control and AAV6-miR-199a respectively for the 30 days time-
point; **P<0.01. I) The scheme represents the protocol used for this study. After 
ischemia/reperfusion and AAV6 direct injection, animals underwent cardiac MRI at day 2 
and at day 30. A group of pigs received BrdU daily from day 2 to day 12 after surgery 
before being sacrificed at day 12 (n=3), while an other set of animals received the 
analogue from day 20 to the day of sacrifice (day 30) (n=3). L and M) Graphs 
representing viral genomes and miR-199a levels respectively in lung, spleen, kidney, 
liver and heart, one month after direct intracardiac injection of AAV6-Control or AAV6-
miR-199a. Data are shown as fold AAV6-Control hearts. Data are mean±SEM; n=3, 
**P<0.01.  
 
Figure 7. miR-199a treatment reduces infarct scar size.  
A) Examples of T2-weighted CMRI image showing cardiac edema (a), with 
corresponding late gadolinium enhancement (LGE) CMR images (b) at day 2 post-MI. B) 
Edema (%LV) at two days after MI. Data are mean±SEM; n=4 AAV6-Control, n=5 AAV6-
miR-199a. C) LGE mass (g) and size (%LV), at day 2 and day 28 post-MI. Data are 
mean±SEM; n=5 per group at day 2; n=9 AAV6-Control and n=10 AAV6-miR-199a at day 
30; *P<0.05. D and E) Gross anatomy of cardiac slices with corresponding LGE-MRI 
images in representative AAV6-Control and AAV6-miR-199a treated pig hearts, at 28 
days post-MI. F) Cardiac MRI representative images of AAV6-Control and AAV6-miR-
199a treated pig hearts 2 and 28 days after MI, from heart apex (a) to base (e) as shown 
in the schematic representation (G). H) Identification of infarct scar and gray zone by 
LGE-MRI. I) Infarct gray zone, infarct core and their ratio 28 days post-MI measured by 
LGE-MRI. Data are mean±SEM; n=9 AAV6-Control and n=10 AAV6-miR-199a; *P<0.05. 
 
Figure 8. miR-199a delivery improves global and regional cardiac function.  
A) LV ejection fraction (EF, %) and (B) stroke volume (ml) measured by cMRI in non 
infarcted controls and infarcted animals at day 2 and day 28 post-MI and AAV6-Control 
and AAV6-miR-199a injection. C and D) LV end systolic and end diastolic volumes (ml) 2 
and 28 days after MI and treatment injection, measured by cMRI. Data are mean±SEM; 
numbers in the bar graphs indicate the sample size; *P<0.05. 
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Figure 9. AAV6-miR-199a injection after ischemia/reperfusion ameliorates regional 
contractility.  
A) An example of cardiac short axis image with the tagging grid in diastole and systole. 
B) Subdivision of the LV short axis in 8 circumferential segments and their 
corresponding infarct core, border zone and the remote zone. The syringe indicates the 
border injected with AAVs. IS, inferoseptal; S, septal, AS, anteroseptal; A, anterior; AL, 
anterolateral; L, lateral; IL, inferolateral; I, inferior. C and D) Eight-segment curves 
corresponding to LV radial (LVErr) (C) and circumferential (LVEcc) (D) strain at 28 days 
after MI. E) Schematic example of calculation of the area under curve (AUC) in arbitrary 
units. F and G) AUC for Err (F) and Ecc (G). H) Percent segmental LV end-systolic wall 
thickening (LVWT). I) AUC for LVWT. Numbers in the bars indicate the sample size. Data 
are mean±SEM;. *P<0.05 vs Sham, #P<0.05 vs AAV6-control at day 28. 
 
Figure 10. AAV6-miR-199a injection increases the number of cells in S-phase.  
A) Schematic representation of the experimental procedure. Briefly, animals underwent 
ischemia-reperfusion and concomitant AAV6 injection. At day 2 after surgery, they were 
daily injected with BrdU until sacrifice at day 12. B) Representative images of BrdU 
immunostaining in the infarct border zone of AAV6-Control- and AAV6-miR-199a-
treated animals, 12 days post MI. C) Quantification of BrdU-positive cardiomyocytes 
over the total number of cardiomyocytes in AAV6-Control and AAV6-miR-199a treated 
animals, 12 days post MI. Data are mean±SEM; n=3 per group; *P<0.05. D) Schematic 
representation of the experimental procedure. Operated and injected animals received 
BrdU daily from day 20 to sacrifice at day 30. E) BrdU immunostaining in the infarct 
border zone of AAV6-Control- and AAV6-miR-199a-treated animals, 30 days post MI. F) 
Quantification of BrdU positive cardiomyocytes over the total number of 
cardiomyocytes in AAV6-Control- and AAV6-miR-199a-treated animals, 30 days pot MI. 
Data are mean±SEM; n=3 per group; *P<0.05. Scale bar=100 μm. 
 
Figure 11. AAV6-miR-199a injection induces heart regeneration after MI by 
increasing cardiomyocyte proliferation.  
A and B) Representative Ki-67 immunohistochemistry images of AAV6-Control- and 
AAV6-miR-199a-treated pigs 12 days after surgery, and relative quantification. Data are 
mean±SEM; n=3 per group; *P<0.05. C and D) Representative Ki-67 
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immunohistochemistry images of AAV6-Control- and AAV6-miR-199a-treated pigs 30 
days after surgery and relative quantification. Data are mean±SEM; n=3 per group; 
*P<0.05. E and F) Phospho-histone 3 immunofluorescence images of pig heart sections 
12 days after MI and AAV injection and relative quantification. Data are mean±SEM; n=3 
per group; *P<0.05. G and H) Phospho-histone 3 immunofluorescence images of pig 
heart sections 30 days after MI and AAV injection and relative quantification. Data are 
mean±SEM; n=3 per group. I and L) Graphs represent variations between 12 and 30 
days, of the percentage of positive Ki-67 (I) and phospho-histone 3 (L) cardiomyocytes 
over the total number of cardiomyocytes. Data are mean±SEM; n=3. M) Aurora B 
immunofluorescence images showing localization in the nucleus or in midbodies, in 
AAV6-miR-199a treated animals, 12 days post MI. Scale bar= 100 μm. 
 
Figure 12. AAV6-miR-199a treatment significantly reduces scar size one month after 
ischemia-reperfusion.  
A) Azan Mallory tricrome staining representative images of transverse heart sections of 
AAV6-Control and AAV6-miR-199a injected pig hearts one month after surgery. B) 
Quantification of infarct size. Data are mean±SEM; n=3 per group;  *P<0.05. Scale bar= 
250 μm. 
 
Figure 13. AAV6-miR-199a treatment after ischemia-reperfusion enhances GATA+ 
cytoplasmic localization in pig myocardium. 
A and B) GATA4 immunohistochemistry representative images in AAV6-Contro- and 
AAV6-miR-199a-injected pigs, 12 days after treatment and quantification of cells 
showing GATA4 cytoplasmic localization (B). Data are mean±SEM; n=3. *P<0.05. C and 
D) GATA4 immunohistochemistry representative images in AAV6-Control- and AAV6-
miR-199a-injected pigs, 30 days after treatment and quantification of cells showing 
GATA4 cytoplasmic localization (B). Data are mean±SEM; n=3. *P<0.05. E, F, G and H) 
Images of desmin (E), myogenin (F), endotelin receptor 1 (G) and Wt1 (H) 
immunohistochemistry on AAV6-Control- and AAV6-miR-199a-treated pigs, 30 days 
after infarction. Scale bar=100 μm. 
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Figure 14. AAV6-miR-199a injection reduces cardiomyocyte area 1 month after 
infarction.  
A) Lectin immunofluorescence and PAS staining images on sham, AAV6-Control- and 
AAV6-miR-199a-treated pig sections, 30 days after infarction. B) Cardiomyocyte cross-
sectional area (μm2) quantification of sham, AAV6-Control- and AAV6-miR-199a-
treated pig sections, 30 days after infarction. Data are mean±SEM; n=3 for Sham group, 
n=5 for AAV6-Control and AAV6-miR-199a-treated pigs. C) Representative picture of 
sham, AAV6-Control- and AAV6-miR-199a-treated pig hearts sectioned in slices of 1 cm 
starting from the apex to the base. Scale bar=100 μm. 
 
Figure 15. AAV6-miR-199a injection reduces pathological hypertrophy  up to 2 
months after infarction and increases contractility.  
A and B) MYH6/MYH7 ratio quantification by qRT-PCR, in sham, AAV6-Control and 
AAV6-miR-199a treated pig hearts, 12 days (A) and one month (B) after surgery. Data 
are mean±SEM; n=3 for 12 days, n=5 for the other time-point. *P<0.05. C and D) BNP 
quantification by qRT-PCR, in sham, AAV6-Control and AAV6-miR-199a treated pig 
hearts, 12 days (C) and 1 month  (D) after surgery. Data are mean±SEM; n=3 for 12 days, 
n=5 for the other time-point. *P<0.05. E and F) ANP quantification by qRT-PCR, in sham, 
AAV6-Control and AAV6-miR-199a treated pig hearts, 12 days (E) and 1 month (F) after 
surgery. Data are mean±SEM; n=3 for 12 days, n=5 for the other time-point. *P<0.05. 
 
Figure 16. Long-term expression of miR-199a causes sudden death.  
A) The Kaplan Meier curve represents mortality after myocardial infarction and AAV6-
Control (n=6) and AAV6-miR-199a (n=7) injection. B) Cardiac MRI representative images 
of AAV6-Control and AAV6-miR-199a treated pigs, 2 days, 1 month and two months 
after myocardial infarction. C) Hematoxylin and eosin, Ki67, CD45, CD34, GATA4, 
desmin, myogenin, caldesmon and HHF35 immohistochemistry and 
immunofluorescence representative images on AAV6-miR-199a treated pig heart 
sections, 2 months after surgery. Scale bar = 100 μm. 	
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Figure 17. miR-199a long-term-expression causes ventricular fibrillation.   
The image represents the ECG tracked by a subcutaneously implanted recorder (Reveal 
Medtronic) during an episode of tachyarrhythmia evolved into ventricular fibrillation in 
an AAV6-miR-199a treated animal, 7 weeks after surgery. 	
 
Figure 18. Comparing different commercial lipid formulations to deliver miRNA 
mimic in vitro and in vivo.  
A and B) Neonatal rat cardiomyoctes were transfected with an siRNA against the UBC 
gene, which is essential for cell viability, using different commercial lipid formulations. 
Three days after transfection, cell viability and toxicity were assessed by 
immunostaining for α-sarcomeric actinin to detect cardiomyocytes or by measuring 
ATP production. White bars represent the percentage of dead cell compared to the 
untreated control, thus indicating transfection efficiency. Black bars represent the 
toxicity of each lipid when delivered alone, in the absence of UBC siRNA. Panel A 
represents efficiency and toxicity of selected lipid formulations assessed by 
cardiomyocyte specific α-s sarcomeric actinin immunostaining. Panel B represents 
efficiency and toxicity of the same lipid formulations assessed by ATP production. Data 
are mean±SEM of 5 independent experiments; *P<0.05, **P<0.01. C) The graph 
represents miR-199a-3p level quantification 2 days after intracardiac injection using the 
indicated lipid formulations. Data are mean±SEM; n=6 per group; *P<0.05, **P<0.01. D) 
MiR-199a-3p target mRNA (Homer1 and Clic5) levels 2 days after intracardiac injection 
using the indicated lipid formulations. Data are mean±SEM; n=6 per group; *P<0.05, 
**P<0.01. E) MiR-199a-3p levels in the indicated organs 2 days after intracardiac injection 
using Lipofectamine RNAiMax (black bars). White bars represent miR-199a-3p in cel-
miR-67 injected animals, thus represent miR-199a-3p endogenous levels. Data are 
mean±SEM; n=6 per group; *P<0.05, **P<0.01. 
 
Figure 19. MiR-199a-3p mimic persistence after RNAiMax-mediated intracardiac 
injection.  
A) Experimental workflow of the procedure. B) MiR-199a-3p levels in free left ventricle 
anterior wall, 2, 4, 8, 12 and 20 days after intacardiac injection. Grey line represents miR-
199a-3p levels in cel-miR-67 injected animals, thus represent miR-199a-3p endogenous 
levels, while black one represents miR-199a-3p injected mice. Note that qRT-PCR 
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primers do not discriminate between endogenous microRNA and mimic. Data are 
mean±SEM; n=6 per group; *P<0.01. C, D, E and F) Homer1 and Clic5 mRNA levels in cel-
miR-67 (control) and miR-199a-3p injected hearts, 2, 4, 8, 12 and 20 days after surgery. 
Data are mean±SEM; n=6 per group; *P<0.01. 
 
Figure 20. MiR-199a-3p mimic injection improves survival and heart function 
parameters after myocardial infarction.  
A) The Kaplan Meier curve shows mortality after myocardial infarction induction and 
cel-miR-67 (control, n=13, light grey) and miR-199a-3p (n=20, dark grey) mimic 
injection. B, C and D) Graphs represent LV ejection fraction, fractional shortening and 
internal diameter measured by echocardiography, 1, 2, 4 and 8 weeks after myocardial 
infarction and mimic injection. Data are mean±SEM; n=13 and n=20 respectively per 
group; *P<0.05, **P<0.01. 
 
Figure 21. MiR-199a-3p mimic injection improves cardiac wall thickness after MI.  
A, B and C) Left ventricular anterior wall (LVAW) thickness at end-systole and end-
diastole and interventricular septum (IVS) thickness at end-diastole were assessed by 
echocardiography. Data are mean±SEM; n=13-20 per group; *P<0.05 relative to Control 
(cel-miR-67). 
 
Figure 22. MiR-199a-3p mimic treatment after MI does not increase cardiomyocyte 
cross sectional area.  
A) Representative images of cardiomyocyte cross-sectional area in non-infarcted 
animals and in infarcted animals after miRNA mimic treatment at day 12 after MI. B) 
Quantification of cardiomyocyte cross-sectional area relative to Control (untreated 
animals).  Data are mean±SEM; n=6 per group; *P<0.05. Scale bar= 100 μm. 
 
Figure 23. MiR-199a-3p mimic injection reduces scar size after myocardial infarction 
by increasing cardiomyocyte proliferation. 
A) Masson’s tricrome staining representative images of transverse heart sections of cel-
miR-67 (control)- and miR-199a-3p mimic-injected mice after myocardial infarction. B) 
Quantification of infarct size. Data are mean±SEM; n=13 and n=20 respectively per 
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group; *P<0.05, **P<0.01. C and D) EdU immunofluorescence representative images of 
myocardial infarction and cel-miR-67 (control) or miR-199a-3p mimics injected animals 
12 days after surgery and relative quantification. Data are mean±SEM; n=6; **P<0.01. E 
and F) Phospho-histone H3 immunofluorescence in myocardial infarction and cel-miR-
67 (control)- or miR-199a-3p mimic-injected animals, 4 days after surgery and relative 
quantification. Data are mean±SEM; n=6; **P<0.01. G and H) Aurora B nuclear (upper 
image) and in midbodies (lower image) immunostaining in myocardial infarction and 
miR-199a-3p mimic injected animals, 4 days after surgery and relative quantification. 
Data are mean±SEM; n=6; **P<0.01. I and L) Visualization of TUNEL+ cardiomyocytes in 
infarcted and injected animals 2 days after surgery. Representative images (I) and 
quantification (L) are shown. Data are mean±SEM; n=6. Scale bar=50 μm. 
 
Figure 24. miR-199a-3p mimic chemical modifications increases neonatal rat 
cardiomyocyte proliferation.  
A) List of different miR-199a-3p mimic chemical modifications and their relative 
commercial suppliers. B and C) EdU immunofluorescence representative images of 
neonatal rat cardiomyocytes 72 hours after transfection with miR-199a-3p mimics 
carrying chemical modifications or cel-miR-67 (Control) and relative quantification. Data 
are mean±SEM of 3 independent experiments. **P<0.01. D and E) Clic5 and Homer1 
mRNA levels in cardiomyocytes transfected with cel-miR-67 (Control) or miR-199a-3p 
mimics carrying chemical modifications 72 hours after treatment. Data are mean±SEM 
of 3 independent experiments. **P<0.01. Scale bar= 100 μm. 
 
Figure 25. miR-199a-3p mimic chemical modifications stability upon intracardiac 
injection in mice.  
A, B and C) Graphs represent the quantification of miR-199a-3p levels upon miR-199a-
3p Dharmacon, Exiqon3 and IDT mimics intracardiac injection, 2, 8 and 21 days after 
surgery. MiR-199a-3p mimic levels were normalized with respect to the amount of the 
endogenously expressed microRNA (cel-miR-67 injected animals). Data are mean±SEM; 
n=6 per group; *P<0.05, **P<0.01. D, E and F) Homer1 and Clic5 (G, H and I) mRNA levels 
in the left ventricle anterior wall, 2, 8 and 21 days after intracardiac injection. Data are 
mean±SEM; n=6 per group; *P<0.05, **P<0.01.  
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Figure 26. MiR-199a-3p mimic IDT exerts the same beneficial effect after myocardial 
infarction as standard miR-199a-3p mimic.  
Graphs represent LV ejection fraction (A), anterior wall thickness at the end of diastole 
(B) and telediastolic volume (C) measured by echocardiography, 1, 2, 4 and 8 weeks 
after myocardial infarction and mimic injection. Data are mean±SEM; n=6 per group.
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TABLES  
Table 1. List of reagents  
Supplier: List of reagents: 
Applied Biosystems  TaqMan Universal PCR Master mix  
BioOptica Masson’s trichrome staining kit 
BioOptica Bioclear  
CORNING 96 multiwell primaria tissue culture dishes 
Dharmacon microRNAs mimic 
Dharmacon siRNAs smart pool 
Dharmacon siRNA/microRNA resuspension buffer 
Exiqon miRCURY LNA Universal RT microRNA PCR 
Exiqon ExiLENT SYBR Green Master Mix kit  
Falcon Transparent 96 multiwell tissue cultured plates 
Gibco DMEM, low glucose, GlutaMAX™ Supplement, pyruvate   
Gibco DMEM, high glucose, GlutaMAXª Supplement, pyruvate  
Gibco Opti-MEM I Reduced Serum Media  
Invitrogen TRIZOL 
Life Technologies Hoechst 33342 
Life Technologies Fetal bovine serum 
NEST 100 mm tissue cultured dishes 
PerkinElmer ATPlite Luminescence Assay  
Quiagen RNeasy mini kits  
Roche bovine serum albumin (BSA) 
Roche  MagNA Lyser Instrument  
Roche  MagNA Lyser green beads 
Sigma Vitamin B12 
Sigma Trypsin 
Sigma penicillin/streptomycin  
Sigma PARAFORMALDEHYDE 
Sigma Tryton X-100  
Sigma PAS staining kit  
Sigma Eukitt mounting medium  
Sigma Ethanol 
Sigma Chloroform 
Sigma DNAse 
Sigma Eppendorf microtubes  
Sigma Xylene  
Sigma HCl  
Sigma Sodium Borate  
Sigma Tween 20  
Sigma DMSO  
Sigma  BrdU  
Sigma  ketamine 
Sigma  xylazine 
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Thermo Fisher  Taqman probes for qRT-PCR 
Thermo Fisher  Lipofectamine RNAiMAX Reagent 
Thermo Fisher  Falcon Cell Strainers 
Thermo Fisher  M-MLV Reverse Transcriptase  
Thermo Fisher  Triton X-100 
ThermoFIsher Click-IT EdU 594 Imaging kit  
ThermoFIsher EdU 
ThermoFIsher ALEXA-594-α-mouse 
ThermoFIsher ALEXA-488-α-mouse 
ThermoFIsher ALEXA-594-α-Rabbit 
Vectastain  ABC KIT  
Vector  ImmPACT DAB  
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Table 2. List of primers and probes  	
Gene: Probe: Supplier: 
mmu GAPDH Mm99999915_g1 Thermo Fisher  
mmu Clic5 Mm00553931_m1 Thermo Fisher  
mmu Homer1 Mm00516275_m1 Thermo Fisher  
rno GAPDH Rn01775763_g1 Thermo Fisher  
rno Clic5 Rn00585964_m1 Thermo Fisher  
rno Homer1 Rn00581785_m1 Thermo Fisher  
hsa 18S Hs03003631_g1 Thermo Fisher  
ssc GAPDH Ss03375629_u1 Thermo Fisher  
ssc HPRT Ss03388274_m1 Thermo Fisher  
ssc NNPA Ss03394501_g1 Thermo Fisher  
ssc BNP Ss03392411_m1 Thermo Fisher  
ssc MYH6 SscCIP0038305 Biorad 
ssc MYH7 SscCEP0040082 Biorad 
GFP Ac03989638_mr Thermo Fisher  
      
Gene: Primer mix: Supplier: 
hsa U6 
339306 
YP00203907  Exiqon  
hsa 5S 
339306 
YP00203906 Exiqon  
hsa-199a-3p 
339306 
YP00204536  Exiqon  
hsa-199a-5p 
339306 
YP00204494  Exiqon  
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